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  The Src kinase family encompasses eight non-receptor protein tyrosine kinases in 
mammals that regulate signaling pathways in virtually every cell type. Src-family kinases (SFKs) 
share a common regulatory mechanism that requires two intramolecular interactions to maintain 
the inactive state.  These involve binding of the SH3 domain and a PPII helix in the SH2-kinase 
linker and interaction of the SH2 domain and a phosphotyrosine residue in the C-terminal tail. To 
compare the activation dynamics of the individual SFKs, a synthetic SFK SH3 domain-binding 
peptide (VSL12) was used to probe the sensitivity of SFKs to SH3-based activation. Surface 
plasmon resonance was used to confirm equivalent binding of the VSL12 peptide to the SH3 
domains and near-full-length kinases. SFKs were tested with VSL12 in a kinetic kinase assay to 
measure the changes in the rate of activity induced by SH3:linker displacement. All SFKs tested 
were susceptible to activation, but to varying degrees. Further, autophosphorylation of the c-Src 
and Hck activation loops prior to VSL12-induced activation revealed that c-Src can achieve a 
higher level of activation if primed before SH3 domain displacement. These results suggest that 
distinct activation thresholds may exist for individual SFKs. To apply these findings in an 
inhibitor discovery setting, the interaction of c-Src with focal adhesion kinase (FAK) was 
studied. FAK activates c-Src by binding to its SH2 and SH3 domains and disrupting their 
regulatory influence on the kinase domain. The c-Src:FAK complex plays a major role in the 
migration and invasion of both normal and cancer cells, making it an attractive target for drug 
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discovery. To test the idea that FAK binding induces allosteric changes in the kinase domain 
active site, a screening assay was developed to target these changes with small molecule 
inhibitors. Assay conditions were identified where c-Src activity was dependent on a 
phosphopeptide encompassing the FAK SH3- and SH2-binding motifs for c-Src. A focused 
library of kinase-biased inhibitors was screened to identify compounds displaying selectivity for 
the c-Src:pFAK peptide complex. An aminopyrimidinyl carbamate, WH-4-124-2, was 
discovered that showed five-fold selectivity for the complex. Molecular docking studies of this 
inhibitor on the kinase domain of Lck bound to imatinib suggest that WH-4-124-2 is a “Type II” 
kinase inhibitor that prefers the unphosphorylated, “DFG-out” conformation of the kinase. 
Selective inhibitors of a specific FAK-induced c-Src conformation may provide a unique 
approach to selective targeting of this key cancer cell signaling pathway.  
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1.0  INTRODUCTION 
1.1 SRC FAMILY KINASES 
The Src-Family Kinases (SFKs) are a family of eight non-receptor protein tyrosine 
kinases with multiple members expressed in virtually every cell type in humans. Long before the 
discovery of c-Src, Sir Peyton Rous discovered in the early 1900s that a virus could cause tumor 
growth in chickens (1). This virus was later identified as the Rous Sarcoma Virus (RSV) and was 
the first description of cancer caused by a virus. It was not until the 1970s that v-Src was 
identified as the causative agent of cancer in the RSV genome, followed soon after by the 
discovery of the cellular homolog, c-Src (2, 3). Subsequently, the remaining family members 
were identified in the human genome. Three family members, c-Src, Fyn, and c-Yes, are 
ubiquitously expressed, while the rest of the family members, Hck, Lyn, Fgr, Lck, and Blk, show 
a more restricted expression pattern, mainly in hematopoietic cell lineages (4). Three additional 
kinases, Srm, Brk, and Frk are also considered relatives to the Src-kinase family, but their 
regulation is not as well defined (5). The SFKs are involved in a variety of signaling pathways 
that control many different cellular processes, including proliferation, cell adhesion and 
migration, cell survival, and the immune response. The sections below will detail the structure 
and regulation of the kinase family, the cellular events triggered by kinase activation, and the 
consequences of deregulation of kinase activation. 
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1.1.1 Structure and Regulation 
The SFKs share a common domain organization and downregulated conformation (Figure 1). 
 
Figure 1. X-ray crystal structure of c-Src in the downregulated conformation 
The structure of c-Src in the downregulated conformation is representative of the eight members of this kinase 
family in mammals. The domain organization is shared by all family members: SH3 domain, red; SH3-SH2 
connector, dark gray; SH2 domain, blue; SH2-kinase linker, orange; kinase domain N-lobe, pink; αC helix, green; 
activation loop, purple; kinase domain C-lobe, light gray; C-terminal tail, cyan. The side-chains of the regulatory 
tyrosines, Y416 and Y527, chicken Src numbering, are shown, where Y527 is phosphorylated. The SH3 domain 
interacts with the SH2-kinase linker and the SH2 domain interacts with the phosphotyrosine tail to maintain the 
downregulated state of the kinase. PDB ID: 2SRC (6) 
 
The N-terminus contains lipid modification sequences for myristoylation and, in some cases, 
palmitoylation (7). Lipid modification is necessary for the localization of the SFKs to the cell 
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membrane for interaction with other proteins. Following these lipid modification sequences is 
the unique domain, where the sequence homology between family members is lowest. This is 
followed by the SH3 domain (which binds polyproline sequences), the SH2 domain (which binds 
phosphotyrosine-containing sequences), a bi-lobed kinase domain, and a regulatory C-terminal 
tail containing a conserved tyrosine residue important for regulation of kinase activity. This C-
terminal tyrosine is phosphorylated by the C-terminal Src kinase (Csk), or the closely related 
kinase Chk, and can be dephosphorylated by a number of phosphatases, including CD45 . 
The x-ray crystal structures of c-Src and Hck in the downregulated, inactive conformations have 
been solved and the structure of c-Src is shown in Figure 1 (6). Two intramolecular interactions 
occur within the kinase to maintain the inactive state; one between the SH3 domain and SH2-
kinase linker, and the other between the SH2 domain and C-terminal tail. The SH3 domain binds 
the polyproline type II (PPII) helix formed in the linker and the SH2 domain binds the conserved 
tyrosine residue in the tail when it is phosphorylated. Displacement of either one or both of these 
interactions leads to kinase activation. These interactions will be discussed in more detail in the 
sections below.  
1.1.1.1 Phylogeny 
While the Src-kinase family is comprised of eight members in mammals, the 
phylogenetic tree of all non-receptor protein tyrosine kinases shows that the eight members can 
be broken down into two distinct subfamilies (Figure 2) (13). Subfamily A consists of c-Src, c-
Yes, Fyn, and Fgr, while subfamily B consists of Hck, Lyn, Lck, and Blk. Alignment of the full-
length or individual domain sequences of all eight kinases results in the same subfamily 
breakdown. Analysis of the sequence alignment of the eight family members shows the most 
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obvious divergence between the subfamilies in the SH2-kinase linker and the C-terminal tail 
(Figure 3).  
 
Figure 2. Phylogenetic tree of non-receptor protein tyrosine kinases 
Sequence alignment of the SH2 domains of all non-receptor protein tyrosine kinases in the human kinome results in 
this phylogenetic breakdown. The subfamily A SFKs are shown in blue and the subfamily B SFKs are shown in red. 
Tree adapted from Filippakopoulos,P., et al. (13).  
 
There are specific differences that may contribute to the diversity in regulation of not only the 
subfamilies, but also the individual family members. The most obvious sequence divergence in 
the linker region is that there is only one proline in the SrcA subfamily member linkers, while all 
members of the B subfamily have two. Despite this difference, the PPII helix still forms in the c-
Src linker and binds to the SH3 domain (Figure 1). Section 1.1.1.2 will explain more about SH3 
ligand binding and Section 1.1.1.4 will give more detail regarding the SH2-kinase linkers. 
In the C-terminal tail, Y527 (chicken c-Src numbering, used throughout) is conserved 
among all family members and is essential for downregulation of kinase activity. However, the 
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sequence following the tyrosine differs between the subfamilies and could have an effect on 
specificity of ligands that activate the kinases via SH2:tail displacement. More about the kinase 
regulation by SH3 and SH2 domain interactions will be discussed in the following sections. 
 
 
Figure 3. Sequence alignment of SH2-Kinase linker and C-terminal tail regions of SFKs 
The sequence alignment of the SFK SH2-kinase linkers and C-terminal tails is shown to highlight the sequence 
diversity between the SrcA and SrcB subfamilies. The optimal Class II SH3-binding sequence is shown and the 
linker residues that fit the consensus sequence are indicated in bold. The optimal SH2-binding sequence is shown 
and the conserved tail tyrosine is indicated in red in the C-terminal tail alignment. 
 
1.1.1.2 SH3 Domain  
The Src Homology 3 (SH3) domain is a modular protein domain composed of roughly 60 
amino acids and is found in many signaling proteins. The SH3 domain was identified as a 
conserved protein domain in the late 1980s after the sequences of other proteins were found to be 
homologous with a region of c-Src, now identified as residues 85-140 (14). The three-
dimensional structures of the isolated SH3 domains of multiple proteins have been solved by 
both x-ray crystallography and NMR, including many members of the Src-kinase family (15, 
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16). SH3 domain structures are highly conserved, and in the case of the SFKs, the SH3 domain 
portion of the near-full length structure does not change from the structure of the isolated SH3 
domain.  
SH3 domains interact with other signaling molecules through binding to PPII helices. 
This principle was first discovered in a screen for peptides that bound to the SH3 domain from 
the non-receptor protein tyrosine kinase c-Abl (17). The c-Abl tyrosine kinase has a very similar 
core structure to the SFKs and shares a similar mechanism of downregulation, such that the 
SH3:linker interaction is important for maintaining the inactive state of the kinase (18). The 
screen resulted in the discovery of the consensus sequence for Abl SH3 binding, 
XPXXXPPPFXP, where X is any amino acid. Subsequently, a peptide library was screened to 
determine the consensus sequences for c-Src and PI3K SH3 binding, which were found to be 
RXLPPLPR, where  represents a hydrophobic residue, and RXLPPRPXX, respectively (19). 
Therefore, while SH3 domains are structurally very similar, their selectivity for polyproline 
sequences differs based on the sequence of the SH3 domain itself. Further studies showed that 
despite the similarity between c-Src and c-Abl, peptides selected as high-affinity for the c-Abl 
SH3 domain did not bind to the c-Src SH3 domain, and vice versa (19).  
Examination of SH3-binding sequences has led to the division of these sequences into 
two distinct classes based on their binding orientation: Class I ligands, which share the consensus 
sequence RXLPPXP, and Class II ligands, which conform to XPPLPXR. Residues flanking these 
sequences can enhance the affinity for the SH3 domain. Many SH3 domains, including those of 
the SFKs, can bind proline-rich sequences in either orientation. Figure 4 diagrams the two 
orientations of ligand binding by SH3 domains, with the c-Src SH3 domain residue numbering.  
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Figure 4. Class I and Class II ligand binding orientations to the c-Src SH3 domain 
The c-Src SH3 domain residues Y90, Y92, D99, W118, and Y136 are shown in boxes on the planar surface of each 
panel. The Class I ligand bound in the top panel has the sequence R1ALPPLP7RY (corresponding to R1-P7), while 
the Class II ligand bound in the bottom panel has the sequence AFA3PPLPRR9 (A3-R9), with the core sequence, 
XPPXP, underlined. The designation between Class I and Class II ligands is dependent on the location of the R 
residue (in bold), which is N-terminal to the consensus sequence in Class I ligands and C-terminal to the consensus 
sequence in Class II ligands. Residues bound to sites P-3-P3 are shown in Table 1. Figure adapted from Dalgarno, et 
al. (20). 
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Three hydrophobic sites are formed by conserved SH3 domain residues. Site 1 binds the R 
residue in the ligand and is formed by D99 and W118 in the SH3 domain, which is considered 
the P-3 position of the SH3 domain. Site 2 is formed by Y92, Y136, and W118 and site 3 is 
formed by residues Y90 and Y136. Sites 2 and 3 bind the LP repeats of the consensus sequence. 
In Table 1, the residues that bind to each position in the SH3 domain are listed, summarized from 
Figure 4.  
 
Table 1. PPII Helix binding sites in the SFK SH3 domain 
Position Class I (Consensus RXLPPLP) Class II (Consensus XPPLPXR) 
P-3 R R 
P-2 X R 
P-1 L P 
P0 P L 
P1 P P 
P2 L P 
P3 P X 
The Class I and ClassII polyproline ligand residues that bind to specific positions in the SH3 domain are 
summarized from Figure 4 (20, 21).  
 
Class I ligand binding can be visualized in the crystal structure of the c-Src SH3 domain in 
complex with the high-affinity ligand VSL12 (VSLARRPLPPLP), as shown in Figure 13 (22). 
More about this interaction is discussed in Chapter 2.  
As mentioned previously, one interaction that maintains the downregulated state of SFKs 
involves the SH3 domain and a PPII helix formed in the SH2-kinase linker. The sequences found 
in the SFK linkers bind in a Class II orientation, but are of rather low affinity for their SH3 
domains. Consequently, displacement of the SH3:linker interaction by a high-affinity sequence 
in another protein can activate the kinase. Shown in Figure 5 is an alignment of the SFK SH3 
domains and linker regions.  
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Figure 5. Sequence alignment of Src-family kinase SH3 domains and SH2-kinase linkers.  
The Src-kinase family can be divided into two subfamilies based on sequence homology as shown (A and B 
subgroups). Key hydrophobic residues that contribute to the binding surface are highlighted in bold and marked with 
an asterisk (their positions in the structure of the Src SH3 domain are modeled in Figure 13). The conserved 
aspartate residues (D99) that contribute to VSL12 peptide binding are also bolded and marked with a †. SFK linker 
sequences are more diverse and display suboptimal residues at key positions that face the SH3 domain in the 
inactive state. The positions of linker residues that contact the SH3 domain in the inactive structure of c-Src are 
modeled in Figure 13. 
 
The SH3 domain residues that form the hydrophobic binding pockets are strongly conserved 
among the entire Src-kinase family. The linker sequences are not as conserved and may 
contribute to the specificity of binding partners that activate the SFKs in cells. The binding of the 
c-Src linker to the SH3 domain can be seen in the near-full-length crystal structure. Figure 13 
shows the details of this interaction, which is discussed in more detail in Sections 1.1.1.4 and 2.1. 
While contacts are made between the SH3 domain and linker, the interaction is suboptimal 
relative to high affinity peptide ligands such as VSL12 (Chapter 2).  
1.1.1.3 SH2 Domain 
Src Homology 2 (SH2) domains are modular protein domains that are a common feature 
of all non-receptor protein tyrosine kinases, in addition to being present in many other cellular 
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signaling molecules. SH2 domains were first discovered in the context of v-Fps, the transforming 
tyrosine kinase present in the Fujinami avian sarcoma virus, as a short stretch of amino acids 
adjacent to the kinase domain important for regulation of kinase activity and host range (14, 23). 
Sequence alignment showed that this sequence was conserved in both v-Src and v-Abl, and was 
subsequently named SH2 for Src homology 2. The structures of isolated SH2 domains are 
similar among many different protein families (24-26).  
 
 
Figure 6. SH2 domains from near-full-length and isolated proteins are structurally identical 
The x-ray crystal structure of the isolated c-Src SH2 domain in cyan (PDB ID: 1SPR) (26) is shown aligned to the 
SH2 domain portion of the near-full-length downregulated structure of c-Src in blue (PDB ID: 2SRC). 
 
Figure 6 shows an overlay of the structure of the isolated c-Src SH2 domain with the SH2 
domain portion of the near-full-length downregulated structure, illustrating that they are nearly 
identical and adopt the same three-dimensional structure independently of their overall sequence 
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context. SH2 domains bind to phosphotyrosine-containing sequences and in the SFKs, the SH2 
domain binds to the phosphotyrosine tail to maintain the downregulated state of the kinase. This 
interaction is essential for downregulation of kinase activity, as evidenced by mutational analysis 
(further discussed in Section 1.1.1.6). 
SH2 domains modulate signaling pathways by binding to phosphotyrosine-containing 
sequences (27). The consensus high-affinity SFK SH2 binding sequence was identified as pYEEI 
by using recombinant c-Src SH2 domain protein to pull down peptides from a phosphotyrosine-
peptide library (28). This sequence is found in the hamster polyomavirus middle T antigen, 
which had already been shown to bind and activate the SFKs (29). The consensus sequence for 
SH2 binding varies depending on the SH2 domain, much like the specificity for polyproline 
motifs varies by the SH3 domain. While all of the SFK SH2 domains preferentially bind the 
pYEEI sequence, other families of SH2-containing proteins prefer different phosphotyrosine-
containing sequences. In the c-Src SH2 domain, the phosphotyrosine and pY+3 isoleucine 
residues bind to two hydrophobic pockets in the SH2 domain in a manner that is referred to as a 
two-pronged plug fitting into a socket (30). Many residues in the SH2 domain contribute to the 
formation of these two hydrophobic pockets as identified in the structure of the c-Src SH2 
domain in complex with a pYEEI peptide (26). Figure 7 shows this structure in the absence and 
presence of the peptide with the essential side chains displayed to illustrate the pockets and the 
binding of the peptide.  
The SFK SH2 domains are essential not only for maintaining regulatory control over the 
enzymes, but also for directing the kinases to their targets in the cell to activate various signaling 
pathways. The recruitment of SFKs to multiple targets in the cell via their SH2 domains, 
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including growth factor receptors and focal adhesions, leads to their activation at these sites and 
their involvement in the stimulation of cell proliferation and cell migration.  
 
 
Figure 7. SH2 domain of c-Src unbound and bound to a pYEEI peptide 
The x-ray crystal structure of the c-Src SH2 domain was solved in complex with the peptide EPQY
P
EEIPIYL (26). 
On the left, the SH2 domain is shown without the peptide present to illustrate the pockets that bind to the pY and 
pY+3 residues. The essential side chains referenced in the original publication are shown in a spherical space-filled 
model. On the right, the pYEEI peptide is bound, shown in yellow, with the phosphotyrosine and isoleucine side 
chains shown bound in the respective hydrophobic pockets.  
 
 
1.1.1.4 SH2-Kinase Linker 
The SH2-Kinase linker is a relatively short sequence that is important in the regulation of 
SFK activity. The x-ray crystal structures of both c-Src and Hck in their downregulated 
conformations show that the linker forms a PPII helix and binds to the SH3 domain in a Class II 
orientation to form one of the necessary intramolecular interactions to maintain the inactive 
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kinase state. As described in Section 1.1.1.2, the consensus Class II binding sequence is 
XPPLPXR. The sequence alignment in Figure 3 shows that the SrcA subfamily linkers contain 
only one proline, while the SrcB subfamily linkers contain two prolines. None of the SFK linkers 
contain an arginine residue at the consensus position. Despite this, examination of the c-Src 
crystal structure shows that the linker still forms a PPII helix and interacts with the SH3 domain. 
This single proline binds to the SH3 domain in the P2 position, as expected for a Class II ligand 
(Figure 4, Table 1). The position usually occupied by a proline in the consensus sequence is 
residue Q253 in the c-Src linker. The side chain of this glutamine residue cannot pack into the P-1 
position and points away from the SH3 domain (Figure 13). The P-3 position normally occupied 
by arginine in the consensus sequence is L255 in c-Src, which points away from the SH3 domain 
and contacts the kinase domain between residues Y326 and W286. No other significant contacts 
between the c-Src linker and the SH3 domain are made, but in the context of the downregulated 
conformation, the interaction persists.  
The Hck linker contains two proline residues and also forms a PPII helix as seen in the 
crystal structure of Hck in its downregulated conformation (Figure 8), demonstrating that this 
general aspect of downregulation is conserved across the A and B subfamilies of SFKs. The 
binding of the linker is different for Hck, which is a subfamily B kinase. This is due to the 
presence of the two proline residues in the linker, which bind in the P-1 and P2 positions of the 
SH3 domain (31).  
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Figure 8. X-ray crystal structure of Hck in the downregulated conformation 
The x-ray crystal structure of Hck in the downregulated conformation was solved by Kuriyan and co-workers in 
1997 (PDB ID: 1QCF) (32). Domain organization and color is the same as in Figure 1 for c-Src. The same 
intramolecular interactions between the SH3 domain and linker and the SH2 domain and phosphotyrosine tail 
observed for c-Src are maintained in the downregulated conformation here.  
 
1.1.1.5 Kinase Domain 
The kinase domain of SFKs is composed of N-terminal and C-terminal lobes and 
resembles the conserved bilobed architecture of all protein kinase domains (33). The kinase 
domain, also considered the Src homology 1 (SH1) domain, adopts a conformation incompatible 
with activity in the downregulated structures of c-Src and Hck. The structure of the active kinase 
domain has been solved for the T-cell Src-family member, Lck (34). To illustrate the differences 
between the active and inactive forms of the kinase domain, they are shown side by side in 
Figure 9. The left panel shows the inactive kinase domain conformation of c-Src, taken from the 
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near-full length downregulated structure where the SH3-SH2 portion of the protein is hidden. 
The right panel shows the structure of the active Lck kinase domain.  
Differences to note in the overall structure in the top panel of Figure 9 are the positions of 
the activation loop and the C helix. In the inactive conformation of c-Src on the left, the 
activation loop physically blocks entry to the substrate binding site. Additionally, Y416 is not 
phosphorylated and is pointed inward towards the hinge region, making it inaccessible for 
phosphorylation. This is also considered the “DFG-in” conformation due to the position of the 
conserved aspartate-phenylalanine-glycine (DFG) motif at the N-terminal end of the activation 
loop. In the active Lck structure on the right, the Y416 is phosphorylated and the activation loop 
flips away from the hinge region, allowing substrate access. The DFG motif flips here to the 
“out” position. 
In the bottom left panel of Figure 9, showing the inactive c-Src kinase domain, the K295 and 
E310 residues are not paired as they would be in an active kinase. Rather, K295 is paired with 
D404 of the DFG motif and E310 is paired with R409 and Y382. On the bottom right in the 
active Lck structure, the C helix rotates inward to position E310 towards K295 so that the K:E 
ion pair can form, which is critical for kinase activity. Now that Y416 is phosphorylated, it pairs 
with R409 and R385. The conserved DFG motif undergoes a flip as well, to the DFG-out 
position. The DFG-in and DFG-out conformations are important in the discussion of kinase 
inhibitor specificity in Section 1.4. 
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Figure 9. Kinase domains of c-Src and Lck in the inactive and active conformations 
The kinase domain portion of downregulated c-Src (PDB ID: 2SRC, left) is shown compared to the active Lck 
kinase domain (PDB ID: 3LCK, right). The N-lobe is displayed in pink, C helix in green, activation loop in cyan, 
and the C-lobe is shown in gray. Critical side chains are displayed to illustrate the changes in specific interactions 
depending on the activation state of the kinase. The top panel shows a view of the entire kinase domains (where the 
tandem SH3-SH2 domains would be on the left side) and the bottom panel shows a zoomed-in view of the hinge 
region with the interactions stabilizing the active or inactive conformation.  
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1.1.1.6 C-Terminal Tail 
The conserved tyrosine residue, Y527, in the C-terminal tail region of the SFKs is 
essential for the downregulation of kinase activity. Phosphorylation of this residue allows for 
interaction with the SH2 domain to maintain the downregulated state of the kinase. 
Dephosphorylation of pTyr-527 by a phosphatase represents one mechanism of kinase activation. 
The sequence of the SFK C-terminal tail does not fit the consensus of an optimal SH2 ligand, as 
shown in the sequence alignment in Figure 3, so displacement of the SH2:tail interaction by a 
ligand with higher affinity can also result in kinase activation. The sequences of the tails differ 
between SrcA and SrcB subfamilies and this may represent clues towards the specificity of SFK 
binding and pathway activation. Furthermore, in v-Src, the oncogenic viral homolog of c-Src, the 
C-terminal end of the kinase is truncated and lacks the C-terminal tyrosine, resulting in 
constitutive kinase activity (35, 36).  Similarly, experimental substitution of Y527 with 
phenylalanine in the SFKs results in hyperactivation of the kinase (37-41). In fibroblast 
transformation assays, the Y527F mutation results in transformation of the cells, while the wild-
type c-Src protein does not have this effect.  
 The C-terminal tyrosine is regulated by phosphorylation by the C-terminal Src kinase 
(Csk) and the closely related homolog, Chk (10, 12). Csk has a similar domain composition and 
organization as the SFKs with SH3-SH2-kinase. However, there are few similarities in the 
overall structures and regulation of Csk and the SFKs. Csk does not contain tyrosine residues in 
the kinase domain and tail that are analogous to the SFKs, and regulation is different. Csk does 
have a similar activation mechanism, in that it can bind to a number of proteins through its SH2 
domain and become activated (42). Some of these proteins are known substrates of the SFKs, 
suggesting that the SFKs and Csk are involved in a negative feedback loop wherein active SFKs 
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phosphorylate their substrates which then bind and activate Csk. This leads to SFK inactivation 
as Csk phosphorylates the C-terminal tail. Additionally, Csk has been found in complex with 
phosphatases like the PEST (proline-glutamine-serine-threonine) domain-enriched protein 
tyrosine phosphatase (PEP) and PTP-PEST which can dephosphorylate the activation loop of the 
SFKs (43, 44). This supports a mechanism for total inactivation of the SFKs whereby Csk 
phosphorylates the tail and the phosphatase dephosphorylates the activation loop. Furthermore, 
in cases where the SFKs are activated by SH2:tail displacement, these phosphatases may also 
dephosphorylate the SFK binding partner to disrupt the interaction between it and the SH2 
domain. This allows for re-association of the C-terminal tail with the SH2 domain (45).  
Tail dephosphorylation and subsequent activation of the SFKs is mediated by a number 
of phosphatases, though the specific phosphatase responsible depends on the cellular context. 
There is evidence that protein tyrosine phosphatase 1B (PTP1B), receptor protein tyrosine 
phosphatase  (PTP), tandem SH2 domain-containing protein tyrosine phosphatase (SHP1), 
and the transmembrane receptor-like tyrosine phosphatase CD45 each to play a role in tail 
dephosphorylation to activate the SFKs (8, 46-48). More about this mechanism of activation will 
be discussed below.  
1.1.1.7 Activation Mechanisms 
The SFKs can be activated through multiple mechanisms that vary based on the cellular 
context. For full activation, the activation loop Y416 must be phosphorylated. There are multiple 
pathways to this level of activation and each can be initiated by a variety of cellular proteins and 
environments. The fundamentals of each mechanism will be discussed here, and in Section 1.2, 
examples of kinase activation in various physiological contexts will be given. 
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One mechanism of kinase activation is by dephosphorylation of the C-terminal tail, as 
mentioned in the previous section. This leads to the loss of the SH2:tail interaction and results in 
kinase activity. The tail has been shown to be dephosphorylated by multiple phosphatases, 
including PTP1B, SHP1, PTP, and CD45. In Section 1.1.2.2, the role of Lck in the maturation 
and activation of T cells will be discussed, where CD45 is the phosphatase implicated in Lck 
activation.  
A second mechanism of activation is through displacement of one or both of the 
intramolecular regulatory interactions by the binding of high-affinity ligands. The SH2 and SH3 
domains are modular domains that target the SFKs to many signaling pathways throughout many 
different cell types. As the SH3 and/or SH2 domains bind to target proteins, the intramolecular 
interactions that maintain the downregulated state of the kinase are displaced. This relieves the 
kinase domain of the conformational constraints that stabilize the inactive conformation. The 
activation of SFKs in this manner by growth factor receptors will be discussed in Section 1.1.2.1. 
Additionally, the activation of c-Src in this manner by focal adhesion kinase (FAK) will be 
discussed in Section 1.1.2.3 and the implication of this activation event will be covered in 
Section 1.3.  
The kinases are also activated by phosphorylation of the activation loop. Normally, this is 
an autophosphorylation event that occurs after one of the previously mentioned mechanisms 
takes place. Subsequent to regulatory domain displacement as described above, the kinase 
domain reorients the activation loop to allow for substrate access to the active site with the 
activation loop tyrosine extended outward for autophosphorylation. The autophosphorylation of 
the activation loop is thought to be in trans rather than cis, supporting the idea that multiple SFKs 
cluster at one site of activation (49, 50). 
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1.1.2 Physiological Regulation of Src-Family Kinase Activity 
The SFKs have been studied in great detail in knockout mouse models to determine the 
responsibilities and requirements for each family member. Table 2 shows the phenotypes that 
result from the genetic ablation of each individual family member. None of the individual SFK 
knockout mouse models result in an embryonic lethal phenotype indicating that no specific 
family member is required for embryonic development. Since multiple SFKs are expressed in 
every cell type, there likely exists functional redundancy leading to compensation by the 
remaining family members in each knockout model. Individual SFK-null mice were eventually 
crossed to create the triple knockout of c-Src, c-Yes, and Fyn (SYF
-/-
). This triple-knockout is 
embryonic lethal at day E9.5 due to failure to turn (51).  
Table 2. Phenotypes observed in SFK mutant mice 
SFK mutant Phenotype 
c-Src Osteopetrosis 
Fyn 
Impaired memory, defect in thymocyte 
signaling 
c-Yes None observed 
Fgr None observed 
Hck None observed 
Lyn Impaired B-cell function, autoimmunity 
Lck 
Impaired TCR signaling, block in T-cell 
development 
Blk None observed 
Src + Fyn + Yes
a
 Embryonic lethal (E9.5) 
a
 Reference (52) 
Table adapted from Lowell and Soriano, 1996 (53). 
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This required developmental event results in inversion of the germ layers and is essential for the 
embryo to assume the correct position for continued development. There were also multiple 
developmental defects seen in the embryos. Mouse embryonic fibroblasts (MEFs) cultured from 
SYF
-/-
 embryos show a dramatic decrease in migration compared to those from wild type 
littermates. 
1.1.2.1 Growth factor receptor-induced activation of SFKs 
Growth factor receptors are transmembrane receptor tyrosine kinases (RTKs) that 
transmit signals into the cell in response to various growth factors. These signals activate various 
pathways, including JAK/STAT, MAP kinase, and PI3K, which lead to proliferation and survival 
(54-56). The involvement of SFK activity in response to growth factor stimulation has been 
shown for multiple growth factor receptors, including the epidermal growth factor receptor 
(EGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor 
(PDGFR), and colony stimulating factor-1 receptor (CSF-1R). Growth factor stimulation of these 
receptors results in autophosphorylation on their intracellular domains, creating high-affinity 
binding sites for the SH2 domains of SFKs, specifically c-Src and Fyn. Activation by these 
receptors implicates the SFKs in the downstream RTK pathways.  
The earliest studies to connect the activation of SFKs with growth factor receptors were 
in the context of the EGF receptor (57, 58). In these studies, DNA synthesis was measured in 
MEFs in response to EGF. DNA synthesis was increased up to five-fold in cells overexpressing 
c-Src compared to wild type cells. Additionally, it was observed that individual mutation of the 
kinase domain, SH2 domain, or myristoylation sequence of c-Src was enough to prevent this 
increase in DNA synthesis. Mutation of the kinase domain to abolish activity showed that c-Src 
activity was necessary for the induction of DNA synthesis by EGF stimulation, while the SH2 
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domain and myristoylation sequence mutations affected c-Src localization to the EGF receptor 
and cell membrane, respectively. Subsequently, it was shown that the SFKs interact with, and are 
activated by, the CSF-1R (59). This study showed that the SFKs c-Src, c-Yes, and Fyn were all 
activated in response to stimulation of cells with CSF-1, but not when the CSF-1R was mutated 
at Y809. This tyrosine residue is part of the SH2 binding site and when mutated to 
phenylalanine, the binding is prevented and the SFKs cannot associate. This was shown in both 
co-immunoprecipitation experiments and kinase assays with SFKs immunoprecipitated from 
CSF-1-activated cell lysates. Using MEFs derived from the SYF
-/-
mouse, a role for c-Src in the 
FGFR pathway was also established (60). Stimulation of SYF
-/-
 cells with FGF-1 resulted in a 
modest increase in cell proliferation and DNA synthesis. Reintroduction of c-Src in this line 
significantly increased DNA synthesis and cell proliferation response to FGF-1. Prior to this 
study, it was reported that c-Src was not essential for FGF-1-induced cell proliferation (61). 
However, those studies were performed by comparing cells isolated from wild type and c-Src
-/-
 
mice, and compensation from c-Yes and Fyn would likely mask the role of c-Src in this pathway. 
The role of the SFKs in the PDGFR-induced pathways has remained less clear. 
Conflicting evidence is presented regarding the involvement of the SFKs in this pathway, namely 
using the same SYF
-/-
 cells as were used in the FGFR study above. Stimulation of these cells 
with PDGF did not result in an inhibition of DNA synthesis compared to wild type cells (51). 
However, the SYF
-/-
 cells were immortalized by the addition of the SV40 large T antigen. A 
subsequent study implicates this in the requirement of the SFKs in the response to PDGF 
stimulation (62). Multiple other studies have since linked the SFKs to PDGFR signaling, 
supporting their role in this pathway. One study used a SFK inhibitor to show inhibition of DNA 
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synthesis in response to PDGF (63), while another showed that overexpression of catalytically 
inactive c-Src or Fyn inhibited the increase in DNA synthesis in response to PDGF (64). 
1.1.2.2 Role of Lck activity in T-cell activation and maturation 
The C-terminal tail of the SFKs must be phosphorylated to bind to the SH2 domain and 
maintain the downregulated state of the kinase. Multiple phosphatases have been implicated in 
the dephosphorylation of the C-terminal tail to induce kinase activation, as mentioned above in 
Section 1.1.1.6. A well-studied example is in T-cell activation where Lck activity is regulated by 
Csk and the receptor-like tyrosine phosphatase CD45 (65). T cells are activated upon binding of 
antigens to the T-cell receptor (TCR). The first event in the signaling cascade upon antigen 
binding is the activation of SFKs, specifically Lck and Fyn which are the most prevalent family 
members in T cells. Lck is kept in the downregulated state by phosphorylation of the C-terminal 
tail by Csk. Upon antigen stimulation, CD45 dephosphorylates the tail to prime the kinase for 
activation. There is evidence of trans-phosphorylation of the Lck activation loop tyrosine by 
other Lck molecules at the membrane (65). Active Lck phosphorylates the TCR, which creates 
high affinity binding sites for the SH2 domains of ZAP-70, a critical member of the TCR 
signaling cascade. ZAP-70 is phosphorylated by Lck and goes on to activate downstream 
signaling pathways that lead to T cell activation. Lck activity must be tightly regulated in this 
system, because loss of Lck regulation leads to hyperactivation of T cells while Lck deficiency 
leads to lack of T cell activation and immunodeficiency. CD45 is also critical in the pathway, as 
CD45 deficiency results in lower SFK activity and an increase in pY527.  
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1.1.2.3 Focal adhesion kinase-induced activation of c-Src 
Some proteins contain tandem high affinity binding sequences for both the SH3 and SH2 
domains of SFKs. Focal adhesion kinase (FAK) contains SH3- and SH2-binding sequences in 
close proximity and has been shown to bind and activate c-Src (66). The activity of c-Src 
induced by FAK is diminished when one of the FAK binding sites is missing or mutated, 
showing that dual engagement is required for full FAK-induced activity. As described above in 
Section 1.1.1.7, the displacement of the intramolecular interactions in c-Src results in the release 
of the conformational constraints imposed on the kinase domain and exposure of the activation 
loop tyrosine, allowing for autophosphorylation and maximal kinase activity. Once bound, the c-
Src:FAK complex is important in the migration of cells via focal adhesion turnover. This will be 
discussed in more detail in Section 1.3.  
1.1.3 Pathological Roles of Src-Family Kinases 
1.1.3.1 Solid tumor malignancies 
There is no shortage of evidence for the connection of the SFKs to many types of cancer. 
SFKs are shown to be overexpressed in many solid tissue malignancies, including tumors of the 
breast, ovary, and colon (67-70). More importantly, increased c-Src activity is reported in these 
cancers as well. The involvement of SFKs in cell proliferation and survival through activation by 
growth factor receptors (as discussed in Section 1.1.2.1) implicates them in the initiation and 
progression of cancer. A common finding in solid tumors overexpressing c-Src is that growth 
factor receptors are overexpressed as well (71, 72). One example is that of EGFR and c-Src 
overexpression in breast cancer (73). Both EGFR and c-Src are found to be upregulated and 
hyperactive in tumor cells. Not only does the increased activity of just one of these kinases have 
 25 
the potential to overstimulate proliferation and survival pathways, but they are found to have a 
synergistic effect. Since EGFR is overexpressed, the higher density of receptors at the cell 
surface is postulated to result in trans-autophosphorylation of the intracellular domains, even in 
the absence of extracellular growth factor stimulation. Even with normal levels of c-Src 
expression, the increased number of c-Src SH2 binding sites on the EGFR intracellular domains 
can result in constitutively activated c-Src and downstream signaling pathways.  
In addition to the activation of proliferation and survival pathways, c-Src is also 
implicated in migration and invasion of cancer cells and in cancer metastasis (74, 75). These 
effects are facilitated through the c-Src:FAK complex, which is essential for focal adhesion 
turnover. Studies in colorectal cancer have shown that c-Src protein levels rise in the early stages 
of cancer and are then maintained as the tumor progresses (76). In contrast, c-Src activity levels 
continue to rise through each stage of cancer and are highest during metastatic dissemination. 
This observation supports an important role for c-Src in metastatic disease. More about the role 
of the c-Src:FAK complex in cancer will be discussed in Section 1.3.2. and is the major focus of 
Chapter 3. 
1.1.3.2 Hematopoietic SFKs in Chronic Myelogenous Leukemia 
The expression of certain SFKs is restricted to hematopoetic cells, so their involvement in 
blood cancers is not surprising. Hck and Lyn have been implicated in the pathogenesis of chronic 
myelogenous leukemia (CML) (77, 78). CML is caused by a reciprocal chromosomal 
translocation between the breakpoint cluster region (Bcr) locus on chromosome 22 and the c-Abl 
locus on chromosome 8, resulting in the Bcr-Abl oncoprotein (79, 80). The Bcr-Abl protein 
mainly consists of the c-Abl protein, but the N-terminus is replaced with Bcr, so regulation of 
kinase activity is disrupted and the kinase is constitutively active. This initially results in a large 
 26 
expansion in the neutrophil population in the peripheral blood during the chronic phase of the 
disease. Ultimately, CML patients undergo a transition known as blast crisis, in which 
differentiation is disrupted and the disease more closely resembles acute myeloid leukemia 
(AML). 
The SFKs were first implicated in CML when Hck and Lyn were shown to be bound and 
activated by Bcr-Abl (81). Subsequently, it was shown that a kinase-dead mutant of Hck 
suppresses transformation by Bcr-Abl in a myeloid cell line (82). Additionally, Hck was linked 
to Stat5 activation in CML cells (83) and both Hck and Lyn were shown to phosphorylate Bcr-
Abl (84). The absence of these phosphorylation events resulted in lower Bcr-Abl transforming 
ability. This showed that there is a reciprocal relationship between the SFKs and Bcr-Abl as they 
were both shown to bind to and activate each other.  
CML was the first malignancy for which the causative agent was pinpointed, and this 
encouraged the discovery of targeted small-molecule kinase inhibitors of Bcr-Abl. The kinase 
inhibitor imatinib, which was first discovered in a screen for inhibitors of the PDGF receptor 
tyrosine kinase, was an instant success in the treatment of CML as it is a very effective Bcr-Abl 
inhibitor in vivo (85). Unfortunately, resistance to this drug develops in patients due to mutations 
in the drug binding pocket in the kinase domain and elsewhere in the protein (86, 87). 
Underscoring the importance of SFKs in CML, the next successful treatment came in the form of 
dasatinib, a dual SFK/Abl inhibitor (88). Dasatinib is also very successful in the clinic against 
CML by simultaneously inhibiting both Bcr-Abl and the SFKs and can overcome some 
mechanisms of resistance to imatinib.  
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1.1.3.3 The Hck:Nef complex in HIV infection 
The human immunodeficiency virus-1 (HIV-1) encodes multiple accessory proteins 
essential for viral pathogenesis. Nef is an accessory protein that has been implicated in multiple 
aspects of HIV infection and disease (89). More importantly, it is thought to elicit its activity 
through the binding of SFKs (90-92). Nef has been implicated in disease progression to acquired 
immunodeficiency syndrome (AIDS) in animal models of disease and in humans . Expression of 
the Nef protein in a transgenic mouse model resulted in the development of AIDS-like disease, 
even in the absence of HIV infection (93). This is supported by a study in which a group of 
patients were identified as long-term non-progressors (LTNPs), as their disease had not 
progressed to AIDS, even ten years after initial infection (94, 95). The sequences of their viral 
genomes were analyzed and it was discovered that all of them were defective for Nef. These data 
support the idea that Nef is both necessary and sufficient for progression to AIDS. 
Nef itself is an accessory protein that has no catalytic function. It must therefore elicit its 
function through binding to host proteins to have the effects described above. Nef contains a 
polyproline motif shown to have a high affinity for the Hck SH3 domain (90). It has also been 
shown to activate Lyn and, to a lesser degree, c-Src (96). The interaction between SFKs and Nef 
has been well studied biochemically, but the role of SFKs in HIV is less clear. Evidence for SFK 
involvement, however, comes in part from studies of Nef expression in Hck
-/-
 mice. These mice 
show delayed development of AIDS-like disease in comparison to the Nef-expressing transgenic 
mice described above (97).  
Nef has been shown to bind with very high affinity (KD = 0.25 M) to the isolated SH3 
domain of Hck (98). Binding of Nef to Hck can activate the kinase very effectively. The PPII 
helix formed in Nef binds to the SH3 domain in a Class II orientation (99). The specificity of 
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different SFK SH3 domains has been attributed to a single isoleucine residue in the SH3 domain 
(98). This residue is present in Hck, but not in Fyn, to which Nef normally does not bind. 
However, mutation of the residue in Fyn from arginine to isoleucine results in a similar binding 
affinity as Hck SH3 to Nef (KD = 0.38 M). This Fyn SH3 R96I mutant was subsequently used 
in crystallographic studies to solve the structure of Nef in complex with an SFK SH3 domain 
(Figure 10) (99).  
The SH3:Nef structure shows the interaction of the PPII helix formed in Nef with the 
same SH3 domain residues as outlined in Section 1.1.1.2 (Y90, Y92, D99, W118, Y136). 
Interestingly, when Nef activates Hck by SH3 domain displacement, the pY tail stays bound to 
the SH2 domain (unpublished data). This is also supported by evidence in yeast growth 
experiments using Csk to downregulate SFK activity (96).  
The expression of SFKs is toxic in yeast, providing a simple phenotypic readout for SFK 
activity. Co-expression with Csk to phosphorylate the C-terminal tail and downregulate the 
kinase activity reverses this effect. Expression of Nef with Hck leads to higher levels of toxicity 
in yeast, which can no longer be overcome by expression of Csk. This is in contrast to the same 
experiment performed with c-Src. Coexpression of Nef and c-Src results in higher toxicity than 
c-Src expression alone, which is similar to observations with Hck. However, co-expression of 
Csk reverses the toxic effect induced by Nef activation in yeast, suggesting that SH3 domain 
displacement in c-Src is not enough to reach maximal activation. This is also supported by 
evidence of the requirement of both SH3- and SH2-binding sequences for FAK-induced c-Src 
activation, discussed in Section 1.1.2.3. 
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Figure 10. SH3 domain of Fyn R96I mutant in complex with PPII helix of Nef 
The x-ray crystal structure of the core domain of Nef was solved in complex with the SH3 domain of Fyn 
(containing the R96I mutation so that binding could occur). The residues in the SH3 domain (red) that form the 
hydrophobic pockets necessary for PPII helix binding are shown in green (Y90, Y92, D99, W118, Y136). The PPII 
helix of Nef is shown and the side chains of the key residues that bind the SH3 domain are shown with spheres to 
illustrate the fit of the helix into the SH3 domain. 
 
1.2 FOCAL ADHESION KINASE 
Focal Adhesion Kinase (FAK) is a 125 kDa non-receptor protein tyrosine kinase that was 
initially discovered in a pool of tyrosine phosphorylated proteins isolated from RSV-infected 
cells, that localizes to focal adhesions (100). FAK is ubiquitously expressed and deletion in mice 
results in embryonic lethality due to poorly formed vasculature systems (101). The embryos also 
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exhibit failure to turn, similar to SYF
-/-
 embryos, suggesting that the functions that result from 
the cooperation of FAK and the SFKs, particularly cell migration, are essential for development 
(102). FAK is a binding partner of c-Src and both have been implicated in cancer, so this section 
will focus on the functions of FAK that relate to cooperation with SFKs.  
1.2.1 Protein Structure 
The FAK protein is composed of an N-terminal four-point-one/ezrin/radixin/moesin 
(FERM) domain, a central kinase domain, and a C-terminal focal adhesion targeting (FAT) 
domain (Figure 11) (103). Between the FERM and kinase domains is a short linker containing 
high-affinity binding sequences for the c-Src SH3 and SH2 domains. The region between the 
kinase and FAT domains contains proline-rich sequences that serve as docking sites for the SH3 
domains of other signaling proteins. The most complete x-ray crystal structure of FAK is shown 
in Figure 11 in which the protein is truncated after the kinase domain. The structure of the FAT 
domain has been solved in isolation (104), though it is unclear how that portion of the protein 
would fit into the structure of the full-length protein.  
The structure of the FERM domain in the FERM-Kinase construct (Figure 11, gray) is 
identical to the structure of the isolated FAK FERM domain (PDB ID: 2AL6, not shown) (105). 
The FERM domain consists of the F1, F2, and F3 lobes, each having its own unique structure, 
and is important for stabilizing the inactive conformation of FAK (discussed below). The kinase 
domain of FAK resembles the conserved architecture of protein kinase domains with the classic 
bilobed structure (33). The FERM-Kinase structure models the autoinhibited structure of FAK, 
yet the kinase domain shows hallmarks of both an inactive structure and an active structure. This 
will be further discussed in Section 1.2.2.1 regarding the inactive FAK conformation.  
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Figure 11. Focal Adhesion Kinase (FAK) structure and domain organization 
The domain organization of FAK is shown at the top, with an N-terminal FERM domain, a short linker containing 
the c-Src SH3 binding site and the autophosphorylation site Y397 (which becomes a high affinity binding site for 
the c-Src SH2 domain), the bilobed kinase domain, a proline-rich region with binding sites for the SH3 domains of 
other signaling proteins, and a C-terminal FAT domain, which targets the protein to focal adhesions. The bottom 
shows the crystal structure of the autoinhibited protein (PDB ID: 2J0J) (103). The crystallized protein is truncated 
after the kinase domain, so does not include the proline-rich region or the FAT domain. In the crystal structure, the 
kinase domain is shown in red, with the activation loop in green. A short stretch of the activation loop is disordered 
in the structure and is represented by dashed lines. The FERM domain is shown in gray and the linker is shown in 
yellow, with the autophosphorylation site indicated with the arrow. A portion of the linker containing the c-Src SH3 
binding site was also disordered in the structure and is represented with the dashed line.  
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Two regions of the protein in the FERM-Kinase structure are unresolved: a portion of the 
FERM-kinase linker and a portion of the activation loop. The unresolved portion of the FERM-
kinase linker contains the c-Src SH3 binding site, though Y397 is present in the structure. This 
residue is essential for c-Src binding through its SH2 domain (106). That Y397 is not 
phosphorylated in the structure supports an inactive kinase. The disordered activation loop in the 
kinase domain is not surprising, as many kinase domain structures are missing this region due to 
its dynamic nature. The missing section includes the activation loop tyrosine residues, Y576 and 
Y577.  
The C-terminal proline-rich segment is not present in any of the structures of other FAK 
domains. Multiple SH3 binding sites are present in this region which recruit SH3 domain-
containing proteins like p130Cas (107). The x-ray crystal structure of the isolated FAT domain 
has been solved alone and in complex with peptides with sequences from the FAK-binding 
protein, paxillin (108, 109). The FAT domain is responsible for targeting FAK to focal adhesions 
through binding to adapter proteins like talin and paxillin, which bind directly to actin.  
1.2.2 Kinase Regulation 
1.2.2.1 Inactive conformation  
The mechanism of downregulation of FAK kinase activity was determined through 
extensive biochemical analyses (110) and confirmed by the structure of the FAK FERM-Kinase 
construct (Figure 11). Deletion of the FERM domain results in constitutive kinase activation. 
This structure supports a role for the binding of the FERM domain to the kinase domain to 
suppress kinase activity. The main point of contact between the FERM and kinase domains is 
between the F2 lobe of FERM and the C-lobe of the kinase domain. F596 in the kinase domain 
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fits into a hydrophobic pocket formed by residues Y180, M183, V196, and L197 in the F2 lobe. 
Additionally, multiple interdomain hydrogen bonds are formed to stabilize the F2:C-lobe 
interaction. A second interaction is formed between the linker and the N-lobe of the kinase 
domain, involving residues D402, E403, and S463. The linker also binds to the surface of the F1 
lobe of the FERM domain and this interaction makes Y397 unavailable for phosphorylation. 
As mentioned in the previous section, the conformation of the kinase domain does not fit 
exactly into that of an inactive kinase, namely because the K:E ion pair is present (discussed in 
Section 1.1.1.5), which is required for kinase activity. That interaction alone does not necessarily 
drive kinase activity, and other aspects of the kinase structure support an inactive conformation. 
Due to the position of the FERM domain, substrate access to the kinase domain is blocked. In 
addition, while the tyrosine residues in the kinase domain are not resolved in the structure, it is 
likely that they are sequestered within the FERM domain and inaccessible for phosphorylation.  
 
1.2.2.2 Mechanisms of Activation 
The process of FAK activation is stimulated by integrin signaling. Integrins are 
heterodimeric transmembrane receptors with no innate catalytic activity (111, 112) . Integrins 
transduce signals into cells in response to the extracellular environment. When integrins are 
activated by ECM ligand binding, a conformational change occurs in the intracellular domains of 
the integrin dimer starting the process of focal adhesion formation. This conformational change 
can recruit FAK through proteins including talin and paxillin. These actin-binding proteins are 
recruited to activated integrin receptors and recruit FAK via the FAT domain to the focal 
adhesion. Once present at the focal adhesion, interaction of the FERM domain with other 
proteins in the complex leads to release of the autoinhibitory interactions and Y397 undergoes 
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autophosphorylation, creating a high affinity binding site for the c-Src SH2 domain. Binding of 
the c-Src SH2 domain results in activation of c-Src, as discussed previously, and c-Src 
phosphorylates FAK on multiple residues (113-115). Two residues, Y576 and Y577, are in the 
FAK activation loop and phosphorylation of these residues is required for full activation of FAK. 
Phosphorylation of two other residues, Y861 and Y925, is necessary in the recruitment of other 
proteins to the focal adhesion complex, including p130Cas and Grb2. Once phosphorylated by 
the c-Src:FAK complex, p130Cas associates with Crk, while Grb2 binds to SOS, both leading to 
activation of Rho-family GTPases that control actin polymerization and adhesion (115-118).  
1.3 C-SRC AND FAK IN NORMAL CELLULAR FUNCTION AND 
CONSEQUENCES OF KINASE DEREGULATION 
1.3.1 Cell Migration 
Cell migration is a tightly regulated process involving over fifty different cellular proteins 
(119). Cells attach to each other through adherens junctions and to the extracellular matrix 
(ECM) via focal adhesions. Regulation of each type of adhesion is achieved through many 
distinct proteins, but some proteins have a role in both, including c-Src and FAK. The function 
of c-Src in both cell-cell and cell-ECM adhesions is to facilitate disassembly, which is required 
for cell migration (120). Cells lacking FAK or the three ubiquitously expressed SFKS, c-Src, c-
Yes, and Fyn, show a dramatic decrease in the rate of cell migration (51, 121). This is due to the 
decrease in the disassembly of focal adhesions and adherens junctions. 
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1.3.1.1 Cell-cell adhesion  
Adherens junctions are formed between cells through the binding of E-cadherin, a 
transmembrane glycoprotein (122, 123). Extracellular E-cadherin molecules on neighboring cells 
bind to each other and are regulated by the intracellular protein complexes that form and are 
linked to the actin cytoskeleton. The intracellular domain of E-cadherin is linked to the actin 
cytoskeleton by -catenin, -catenin, and p120catenin (124). When signaling events trigger the 
disruption of cell-cell contacts, c-Src is recruited to initiate breakdown of the complex. PTP1B 
co-localizes with c-Src to adherens junctions and has been shown to activate c-Src by 
dephosphorylation of the C-terminal tail (71). Studies in FAK null cells show that FAK is also 
required for the disruption of cell-cell contacts.  
1.3.1.2 Cell-ECM adhesion 
Focal adhesions are formed to facilitate the connection between the extracellular 
environment and the actin cytoskeleton (118). Heterodimeric integrin receptors are 
transmembrane proteins that transmit extracellular signals into the cell. ECM ligand binding to 
integrin receptors induces a conformational change in the intracellular domains that leads to the 
recruitment of actin-binding proteins, including talin and vinculin. FAK is recruited to the focal 
adhesion through its FAT domain, which binds talin. As described in Section 1.2.2.2, FAK 
becomes activated in response to binding other focal adhesion proteins through its FERM 
domain. This leads to subsequent recruitment of c-Src and the formation of the c-Src:FAK 
complex. The activity of c-Src:FAK is responsible for the disassembly of focal adhesions by 
phosphorylating paxillin, which leads to the activation of downstream signaling cascades. To 
prevent disassembly, Csk is also localized to focal adhesions to downregulate c-Src activity until 
the appropriate time (125, 126).  
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1.3.2 Cancer 
One hallmark of cancer cells is the loss of adhesion to other cells and to the extracellular 
matrix (71). As these processes are regulated by c-Src and FAK activity as described above, it is 
not surprising that both are found to be overexpressed and hyperactivated in cancer. At adherens 
junctions, c-Src not only facilitates the disruption of the E-cadherin-catenin-actin complex, but 
also targets E-cadherin for degradation (127, 128). E-cadherin regulates cellular invasion and 
loss of E-cadherin function results in a more invasive phenotype. Further, as the c-Src:FAK 
complex facilitates focal adhesion disassembly, it is not surprising that a hyperactive complex 
results in an increased rate of migration in cancer cells.  
1.4 SMALL-MOLECULE INHIBITORS OF SRC-FAMILY KINASES AND FOCAL 
ADHESION KINASE AS ANTI-CANCER THERAPY 
1.4.1 Overview and History of Kinase Inhibitors 
The first kinase inhibitor to enter clinical trials was the Bcr-Abl inhibitor, imatinib 
(Gleevec), for the treatment of CML (85, 129). This was the first example of a small molecule 
inhibitor targeted to the causative agent of a specific cancer (130). Imatinib was discovered in a 
screen for inhibitors of the PDGF receptor, but was found to also have activity against c-Abl and 
c-Kit. Ultimately, resistance to imatinib develops in patients with advanced CML (131). This led 
to the development of second-generation Bcr-Abl inhibitors like nilotinib and dasatinib, which is 
also a SFK inhibitor (88, 132). The x-ray crystal structures of the Abl kinase domain in complex 
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with imatinib and dasatinib have been solved and are shown in Figure 12 to illustrate the binding 
modes of these compounds to the kinase domain (133-135) .  
Kinase inhibitors can be classified into at least four different types (136, 137). Type I 
inhibitors bind directly to the ATP-binding site in the hinge region of the kinase domain and are 
directly competitive with ATP. Structures of kinases in complex with Type I inhibitors are 
generally found in the active, DFG-in conformation. Type II inhibitors make contact with the 
ATP-binding site, but also with an allosteric pocket in the kinase domain formed when in the 
DFG-out conformation. As the DFG motif rearranges to create this allosteric site, the 
phenylalanine residue partially blocks the ATP-binding site. Consequently, the DFG-out 
conformation is consistent with an inactive kinase. Type III inhibitors only bind to this allosteric 
site in the kinase domain and make no contact with the ATP-binding site, while Type IV 
inhibitors bind at a site completely removed from the catalytic region. Type III and Type IV 
inhibitors will not be discussed here.  
Imatinib is a Type II inhibitor that binds to c-Abl/Bcr-Abl when it is in the DFG-out 
conformation (Figure 12A). While originally thought to only bind to the inactive form of the 
kinase, the crystal structure shows that the K:E ion pairing is present, which is a feature of the 
active conformation. However, the activation loop tyrosine is not phosphorylated and the 
activation loop itself is in a position consistent with an inactive kinase (138). The conformation 
of c-Abl when imatinib is bound likely represents a transition state between inactive and active 
conformations. 
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Figure 12. Binding modes of Bcr-Abl inhibitors imatinib and dasatinib to the c-Abl kinase domain 
The x-ray crystal structure of the kinase domain of c-Abl has been solved in complex with the inhibitors imatinib 
(A, PDB ID: 1IEP) and dasatinib (B, PDB ID: 2GQG). Side chains of key residues are shown. In both structures, the 
K:E ion pair is present. A) Imatinib is a Type II kinase inhibitor that binds not only to the ATP-binding site of the 
kinase, but also to an allosteric site in the kinase domain that is only present in the inactive, DFG-out conformation. 
B) Dasatinib is a Type I kinase inhibitor that binds to the ATP-binding site of the kinase domain and shows no 
preference for the DFG-in or DFG-out conformation. The kinase is in the active, DFG-in conformation in the 
structure. Figure adapted from Panjarian, et al (134). 
 
Conversely, the Type I inhibitor dasatinib shows no preference for the active or inactive kinase 
conformation. The structure of c-Abl with dasatinib bound (Figure 12B) is consistent with the 
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active conformation based on the presence of the K:E ion pair and the position of the activation 
loop. Though the activation loop tyrosine is not phosphorylated (since the kinase activity is 
inhibited by the presence of the drug), the tyrosine still pairs with R386 as it would in an active 
conformation. As mentioned before, dasatinib also binds and inhibits SFKs, which will be further 
discussed in the next section. 
1.4.2 Src-Family Kinase Inhibitors 
Dasatinib (structure in Figure 12B) is a dual SFK/Abl inhibitor that is currently approved 
for the treatment of CML in patients who are resistant to imatinib (88). As the SFKs are 
promising targets for cancer therapy due to their involvement in so many cellular processes, 
dasatinib has been tested in the laboratory setting for its ability to inhibit cancer cell growth, 
migration, and invasion. Dasatinib has shown much promise in these assays, leading to numerous 
clinical trials. Trials are currently in progress to test dasatinib for the treatment of metastatic 
breast cancer, head and neck cancer, glioblastoma multiforme, and metastatic colorectal cancer 
(139-142). Many of the clinical trials are testing dasatinib in combination with other first-line 
chemotherapeutic agents. As discussed above, dasatinib is a Type I, ATP-competitive kinase 
inhibitor. The activity of dasatinib is not restricted to c-Abl and the SFKs, as it also inhibits the 
PDGF receptor, c-Kit, and the ephrin type-A receptor 2 (EphA2). There have been some 
promising results from the clinical trials but at this point, none have led to approval for first-line 
therapy.  
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Saracatinib (AZD0530) 
Saracatinib is a dual SFK/Abl inhibitor as well, with less off-target effects than dasatinib (143). 
No crystallography data is available for this drug in complex with a kinase, but it is known to be 
an ATP-competitive inhibitor. The success of this inhibitor in preclinical trials was similar to that 
of dasatinib and led to multiple clinical trials for the treatment of solid tumors (144). As 
personalized medicine is becoming more attainable, biomarkers are being investigated to 
preselect patients who may respond best to SFK inhibitor treatment. Once these are established, 
this and other SFK inhibitors may be reevaluated in patients who fit these criteria.  
1.4.3 Focal Adhesion Kinase Inhibitors 
As with the SFKs, a role for FAK in cancer metastasis has been established and inhibitors 
of FAK are being investigated as potential anti-cancer agents. There are currently no established 
FAK inhibitors used in the clinic, but there are clinical trials in progress with two compounds, 
PF-562,271 and VS-6068 (defactinib) (145-147). Both compounds were reported to decrease 
pY397 phosphorylation levels, which would be ideal so as to prevent formation of the c-
Src:FAK complex. PF-562,271 was found to be very selective for FAK and the homolog Pyk2 in 
preclinical studies (148-150). Clinical trials with this compound were completed in patients with 
solid tumors of various sites and many patients showed no disease progression. Unfortunately, 
there was no positive partial or complete response reported in any patients. Defactinib is 
currently being investigated for the treatment of mesothelioma, lung cancer, and ovarian cancer 
(145, 146). This compound was very successful in preclinical studies as well, but clinical results 
are still pending. Based on the mechanism of FAK activity in cells, however, it would seem 
likely that using a FAK inhibitor in combination with traditional chemotherapy would be more 
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successful than monotherapy with the inhibitor alone. Many of the effects of FAK are elicited 
through the c-Src:FAK complex, so potential combination of SFK and FAK inhibitors could be 
useful in treatment of metastatic disease. An alternative approach may involve targeting of c-Src 
in the FAK-bound state; this possibility is explored experimentally in Chapter 3. 
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1.5 HYPOTHESIS AND SPECIFIC AIMS 
The SFKs are thought to have redundant roles, yet evidence is accumulating for distinct primary 
functions by specific family members. Many studies have laid the foundation for what we know 
about kinase regulation, yet specifics about the differences between family members have yet to 
be determined. A role for the SFKs in cancer is well established, yet the current state of targeted 
therapies is limited to global SFK inhibition. In light of the differences in the functions of even 
the most closely related family members, I have attempted in this study to gain more insight into 
the diversity in the regulation of the individual members of the Src kinase family, and to exploit 
these differences for targeted inhibitor discovery.  
 
Hypothesis 
The SrcB subfamily of SFKs is more susceptible to activation by SH3:linker displacement alone, 
while SrcA subfamily members rely on additional displacement of the SH2:tail interaction for 
maximal activation.  
 
Specific Aim 1 
Determine whether linker displacement from the SH3 domain is sufficient to induce Src-family 
kinase activation. 
 
Specific Aim 2 
Develop a screening assay for conformation-specific inhibitors of c-Src using high affinity 
natural ligands to induce distinct kinase conformations.  
 
 43 
2.0  DIVERSITY IN REGULATION OF SRC-FAMILY KINASES BY THEIR SH3 
DOMAINS 
2.1 INTRODUCTION 
The Src family of non-receptor protein-tyrosine kinases is the largest tyrosine kinase 
family in the human kinome, with multiple members expressed in virtually every cell type. Three 
Src-family kinases (SFKs), c-Src, Fyn, and c-Yes, are found in most cell types while the 
remaining members have more restricted expression patterns, primarily in hematopoietic cell 
lineages (151). SFKs regulate multiple cellular processes, including proliferation, survival, 
differentiation, adhesion and migration (4). Strict control of SFK activity is essential to normal 
cellular and tissue homeostasis, while deregulation of SFK activity contributes to malignant 
transformation. Increased c-Src expression and activity are both observed in many forms of 
cancer and contribute to tumor cell proliferation, migration, and invasiveness (71). 
All SFKs share a high degree of amino acid sequence homology and identical domain 
organization. The N-terminus of each family member encodes a signal sequence for 
myristoylation, a lipid modification critical to membrane localization. The myristoylation site is 
followed by a relatively short unique domain, which is the only non-homologous region across 
the kinase family. Most SFKs are also palmitoylated within this region, which contributes to 
membrane targeting (152). Following the unique region is an SH3 domain, which binds proline-
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rich sequences that adopt a polyproline type-II (PPII) helical structure, an SH2 domain, which 
binds phosphotyrosine-containing sequences, an SH2-kinase linker, a bilobed kinase domain, 
and a C-terminal negative regulatory tail. All SFKs contain two conserved tyrosine 
phosphorylation sites important for regulation of kinase activity, which serve opposing roles 
(153). Phosphorylation of Y416 (all residue numbering as per the structure of c-Src; PDB code 
2SRC) in the activation loop locks the kinase domain in the active conformation. Conversely, 
phosphorylation of Y527 in the C-terminal tail is required for downregulation of kinase activity. 
This site is phosphorylated by the separate regulatory kinases Csk and Chk (154). 
Biochemical and structural studies have provided detailed insight regarding the 
mechanisms that keep SFKs in the inactive state. Both c-Src and the hematopoietic family 
member Hck have been crystallized in their inactive conformations (6, 31, 32, 155), revealing 
two intramolecular interactions essential for downregulation of kinase activity (Figure 1). One 
interaction involves pY527 in the C-terminal tail and the SH2 domain, while the other includes 
the SH3 domain and the PPII helix formed by the SH2-kinase linker. When both interactions are 
present, the SH3 and SH2 domains pack against the back of the kinase domain to stabilize the 
inactive conformation. In the inactive state, helix αC in the N-lobe is rotated away from the 
active site, preventing a conserved glutamate residue (E310 in c-Src) from forming a salt bridge 
with K295, a conserved interaction critical to the activity of c-Src and virtually all other kinases 
(6, 155). As a consequence, the activation loop adopts a helical structure with the 
autophosphorylation site (Y416) pointed inward. 
Sequence homology and shared domain organization suggest that the structural basis of 
kinase downregulation is conserved across all Src-family members. However, distinct 
mechanisms of kinase activation have been reported for individual SFKs, including displacement 
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of the SH3 domain from the SH2-kinase linker (41), displacement of the C-terminal tail from the 
SH2 domain (156), displacement of both of these intramolecular interactions (66), and trans-
phosphorylation of the activation loop tyrosine by another kinase (153). Further evidence 
suggests that these activation mechanisms may be unique to individual family members. For 
example, Hck is activated by the HIV-1 virulence factor Nef, which binds to the Hck SH3 
domain. SH3 domain engagement by Nef displaces the Hck linker, leading to kinase activation 
without displacement of the tail from the SH2 domain (157, 158). In contrast, both the 
SH3:linker and SH2:tail interactions are disrupted when c-Src is activated by focal adhesion 
kinase (FAK), which contains tandem high-affinity binding sequences for the c-Src SH3 and 
SH2 domains (66).  
Other evidence suggests that individual SFKs serve unique and non-redundant roles 
within the same cell type, despite their close structural homology. Recent work in murine 
embryonic stem (ES) cells provides a dramatic example of this phenomenon. Although c-Src and 
its closest phylogenetic relative, c-Yes, are both expressed in this cell type, c-Src activity drives 
ES cell differentiation while c-Yes suppresses differentiation and drives self-renewal (159-161). 
Along similar lines, RNAi-mediated knock-down of c-Yes expression in colon cancer cell lines 
increased apoptosis and reduced cell migration and tumor growth, while c-Src knock-down 
yielded a much less dramatic effect on the same phenotypes, suggestive of a dominant role for c-
Yes vs. c-Src in colon cancer (162). These differences in individual functions raise fundamental 
questions about what mechanisms selectively regulate specific family members, especially in 
cellular contexts where multiple SFKs are co-expressed. 
Biological evidence for diversity in SFK signaling prompted us to investigate whether 
individual family members are controlled by regulatory domain displacement and 
 46 
autophosphorylation in an equivalent manner. For this study, we focused on four Src family 
members, c-Src, Lyn, Fyn and Hck, because they are broadly representative of the overall Src 
family from a phylogenetic point of view. First, we used a synthetic SH3-binding peptide with 
equal affinity for each of the recombinant purified kinases as an activating ligand. We found that 
all four representative SFKs are susceptible to activation by SH3 domain displacement, but the 
sensitivity to activation by this mechanism varied widely. In addition, we observed a major 
difference in sensitivity to activation of c-Src vs. Hck by SH3 domain displacement following 
autophosphorylation of the activation loop. Overall, these observations suggest that the mode of 
activation (activation loop phosphorylation vs. regulatory domain displacement) may reflect the 
evolution of individual SFKs to accommodate specific signaling environments.  
2.2 MATERIALS AND METHODS 
2.2.1 Cloning, expression, and purification of recombinant SH3 domains.  
The coding sequences for the isolated SH3 domains of human c-Src, Fyn, Hck, and Lyn 
(corresponding to residues 81-142 of c-Src, numbering according to PDB ID: 2SRC) were 
amplified by PCR and subcloned into the bacterial expression vector pET21a (EMD Millipore) 
using NdeI and XhoI restriction sites. The C-terminus of each construct was modified by the 
addition of the sequence LPHHHHHH as encoded by the XhoI site and the His6 tag in the 
vector. E. coli strain Rosetta 2(DE3)pLysS (EMD Millipore) was transformed with each plasmid 
and cultures were grown at 37 °C until the OD600 reached 0.8-1.0. Protein expression was 
induced with 0.4 mM isopropyl -D-thiogalactopyranoside (IPTG) for 4 h at 25 °C. For 
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purification, cell pellets were resuspended in ion-exchange start buffer (20 mM Tris-HCl, pH 
8.5, 5 mM -mercaptoethanol, 10% glycerol), sonicated, and clarified by centrifugation. Soluble 
SH3 domain proteins were purified from the clarified lysates by anion-exchange (HiPrep Q FF; 
GE Healthcare), immobilized metal ion affinity (HiTrap Chelating HP; GE Healthcare), and size-
exclusion chromatography (HiLoad 26/60 Superdex 75; GE Healthcare). Purified SH3 domain 
proteins were buffer-exchanged with HBS-EP (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM 
EDTA, 0.05% v/v P20 surfactant) using Amicon Ultra-15 Centrifugal Filter Units with Ultracel-
10 Membranes (EMD Millipore) for storage and surface plasmon resonance experiments. 
2.2.2 Expression and purification of recombinant SFK-YEEI proteins.  
Human Hck, Lyn, Fyn and c-Src clones were modified on their C-terminal tails to encode the 
sequence Tyr-Glu-Glu-Ile-Pro (YEEI variants), to enable autophosphorylation of the tail and 
high-yield purification in the down-regulated state without co-expression of Csk (163). In 
addition, the N-terminal unique domain of each kinase was replaced with a hexahistidine tag, and 
each construct was used to produce a recombinant baculovirus in Sf9 insect cells using 
BaculoGold DNA and the manufacturer’s protocol (BD Pharmingen) as previously described 
(96). Src-YEEI was co-expressed with the Yersinia pestis YopH phosphatase to promote 
dephosphorylation of the activation loop tyrosine to help downregulate kinase activity (164, 
165). In this case, Sf9 cells were grown in a monolayer and infected with high-titer Src-YEEI 
and YopH baculoviruses. Cells were harvested 72 h after infection for Src-YEEI purification. All 
four kinases were purified as previously described (96). Purified proteins were stored in 20 mM 
Tris-HCl, pH 8.3, containing 100 mM NaCl. 
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2.2.3 Surface Plasmon Resonance (SPR).  
SFK-YEEI proteins were buffer-exchanged with HBS-EP using Amicon Ultra-15 Centrifugal 
Filter Units with Ultracel-10 Membranes (EMD Millipore). SPR experiments were performed 
using a Biacore 3000 Instrument (GE Healthcare) on a streptavidin (SA) biosensor chip. The 
high-affinity Src SH3-binding peptide VSLARRPLPPLP (166) was synthesized and biotinylated 
by the University of Pittsburgh Peptide Synthesis Core. The peptide was solubilized in HBS-EP 
buffer to a concentration of 5 nM, injected onto the SA surface at 10 l/min and immobilized to 
a level of 80 Response Units (RU). A biotinylated IB kinase substrate peptide, 
RHDSGLDSMKD (Enzo Life Sciences), was immobilized to 80 RU on the reference flow cells 
as a control for nonspecific binding of analytes to the peptide SA surface. Each SFK SH3 
domain and corresponding SFK-YEEI protein was injected in duplicate over a range of 
concentrations at 25 °C at a flow rate of 30 l/min. Association was measured for 180 s, 
followed by 300 s of dissociation in HBS-EP running buffer. The chip surface was regenerated 
with HBS-EP buffer after each SH3 domain run or with 0.05% SDS in water after each SFK-
YEEI protein run. In addition to reference flow cell subtraction, HBS-EP buffer-only cycles were 
used to allow double referencing for all analyses. Binding curves were fit using a 1:1 Langmuir 
binding model and the BIAevaluation software v. 4.1.1 (GE Healthcare) which was used to 
generate all kinetic data. 
2.2.4 ADP Quest kinetic kinase assay.  
Kinetic kinase assays were performed using the ADP Quest Assay (DiscoveRx), which 
fluorimetrically monitors the production of ADP (167). Briefly, the conversion of ATP to ADP is 
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coupled to the production of pyruvate from phosphoenolpyruvate (PEP) by pyruvate kinase 
(PK). Pyruvate is converted to hydrogen peroxide by pyruvate oxidase, which in turn oxidizes 
Amplex Red to the fluorescent product, resorufin. Accumulation of ADP is measured as the 
increase in resorufin fluorescence at excitation and emission wavelengths of 530 nm and 590 nm, 
respectively. All assays were performed in quadruplicate in black 384-well microplates (Corning 
Catalog # 3571). ATP stocks (10 mM; Sigma) were prepared in 10 mM Tris-HCl, pH 7.0. The 
SFK substrate peptide (5 mM; sequence YIYGSFK; Anaspec) (168) was prepared in ADP Quest 
assay buffer (15 mM HEPES, pH 7.4, 20 mM NaCl, 1 mM EGTA, 0.02% Tween-20, 10 mM 
MgCl2, 0.1 mg/ml bovine -globulins). Kinase reactions were initiated by the addition of 5 l 
ATP to each well at 10 times the final concentration. The reactions were performed in a final 
assay volume of 50 l/well at 25°C. Assay plates were read at 5 min intervals for 3 h on a 
Molecular Devices SpectraMax M5 microplate reader. 
2.2.5 Substrate and ATP Km determination in the ADP Quest assay.  
To measure the Km for the YIYGSFK substrate peptide, the ATP concentration was held 
constant at 200 M, the maximum tolerated concentration in the assay. ATP is regenerated in the 
assay and is therefore not depleted as a function of substrate phosphorylation. Kinase 
concentrations were held constant at 150 ng/well for Src-YEEI, Fyn-YEEI, and Hck-YEEI, and 
250 ng/well for Lyn-YEEI. The substrate peptide was titrated into the assay at various 
concentrations ranging from 1.95 to 500M. To measure the Km for ATP, the peptide substrate 
concentration was set to the Km for each SFK, and kinase concentrations were held constant as 
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stated above. ATP was titrated into the assay over a concentration range of 6.25 to 200 M. The 
resulting rate data were fit as described below. 
2.2.6 ADP Quest Data Analysis.  
Each ADP Quest assay included controls for non-enzymatic production of ADP and kinase 
autophosphorylation. Raw fluorescence data obtained from quadruplicate wells for each 
condition were averaged and corrected for the non-enzymatic rate of ADP production and SFK 
autophosphorylation. Corrected raw fluorescence units (RFU) were then plotted against time, in 
minutes, to determine the rate of each reaction. Linear regression analysis (GraphPad Prism) was 
performed on the linear portion of each corrected progress curve, and the slope yielded the 
reaction rate. Reaction rates were converted to pmol ADP produced/min using the correction 
factor 4.2 RU/pmol ADP, which was generated from a standard curve under identical reaction 
conditions. For ATP and substrate Km experiments, plots of the reaction rates at each substrate 
or ATP concentration obeyed Michaelis-Menten kinetics and were best-fit by nonlinear 
regression analysis (GraphPad Prism). Km values were determined using the equation, 
v = Vmax[S]/(Km+[S])   (Eq. 1) 
where v = the measured velocity, Vmax = the maximal reaction velocity, [S] = the substrate 
(peptide or ATP) concentration, and Km = the concentration of substrate or ATP at which the 
reaction velocity is half of the maximal velocity. 
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2.2.7 SFK activation by the SH3 binding peptide in the ADP Quest Assay.  
To test each SFK for sensitivity to activation by VSL12, ATP and substrate 
concentrations were set to their respective Km values for each SFK. Kinase concentrations were 
held constant for Src-YEEI (25 ng/well), Fyn-YEEI (30 ng/well), Hck-YEEI (80 ng/well), and 
Lyn-YEEI (120 ng/well), so as to yield a basal reaction rate of about 1 pmol ADP produced/min 
in each case. The VSL12 peptide was solubilized in ADP Quest assay buffer to 10 mM. The 
VSL12 peptide was titrated into the assay from 0.1 to 300 M. VSL12 peptide and kinase were 
pre-incubated for 15 min at 25 °C before the addition of substrate, assay reagents, and ATP. 
To test Src-YEEI and Hck-YEEI for sensitivity to activation by VSL12 after 
autophosphorylation, each kinase was pre-incubated in 550 l of ADP Quest assay buffer with or 
without ATP at the Km for each kinase for 3 h at 25 °C. Following pre-incubation, 
responsiveness to VSL12 activation was assayed as described above. 
Kinase reaction rates at each VSL12 peptide concentration obeyed Michaelis-Menten 
kinetics and were best-fit by nonlinear regression. The Vmax of each kinase reaction in the 
presence of VSL12 was determined using Equation 1. To calculate the activation constant (Kact), 
the basal rate (rate in the absence of VSL12) was subtracted from the rate in the presence of 
VSL12 at each concentration. The transformed rates were plotted against VSL12 concentration. 
The resulting curves also obeyed Michaelis-Menten kinetics and were best-fit by nonlinear 
regression as per the method of Boerner, et al., 1996 (169). Kact was calculated from 
va = Vact[L]/(Kact+[L])  (Eq. 2) 
where va = the measured velocity in the presence of VSL12 minus the velocity in the absence of 
VSL12, Vact = the maximal reaction velocity in the presence of VSL12 minus the velocity in the 
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absence of VSL12, [L] = the VSL12 concentration, and Kact = the concentration of VSL12 at 
which the reaction velocity is half of the Vact. 
2.2.8 Pepsin digestion and peptide analysis.  
For the elucidation of kinase autophosphorylation sites, 50 pmol of Src-YEEI and Hck-YEEI 
were digested online with pepsin in potassium phosphate buffer (150 mM KH2PO4/150 mM 
K2HPO4, pH 2.5). The resulting peptides were separated using a Waters nanoAcquity UPLC 
system (Waters Corp, Milford, MA), trapped and desalted for 3 min at 100 μL/min and then 
separated in 8 min by an 8%–40% acetonitrile:water gradient at 40 μL/min. The separation 
column was a 1.0 × 100.0 mm Acquity UPLC C18 BEH (Waters) containing 1.7 μm particles. 
Mass spectra were obtained with a Waters Xevo-QTOF equipped with standard ESI source 
(Waters Corp., Milford, MA, USA). Mass spectra were acquired over an m/z range of 100 to 
1900. Mass accuracy was ensured by calibration with 100 fmol/μL Glu-fibrinopeptide, and was 
less than 10 ppm throughout all experiments. Identification of the peptic fragments was 
accomplished through a combination of exact mass analysis and MSE using custom IdentityE 
PLGS 2.5 Software from the Waters Corporation (170). MSE was performed by a series of low-
high collision energies ramping from 5-30 V, therefore ensuring proper fragmentation of all the 
peptic peptides eluting from the LC system. 
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2.3 RESULTS 
2.3.1 Structural basis of high affinity VSL12 peptide binding to SFK SH3 domains.  
To test c-Src, Fyn, Hck, and Lyn for their susceptibility to activation by SH3 domain 
displacement, we first identified a peptide ligand with similar affinity for each of their SH3 
domains. VSL12, a 12-mer peptide with the sequence VSLARRPLPPLP, was originally 
discovered in a phage-display screen for sequences that bind to the c-Src SH3 domain in the low 
micromolar range (166). Subsequent structural studies showed that VSL12 binds to the Src SH3 
domain through a polyproline type II helix found in the C-terminal end of the peptide, with the 
adjacent arginine making contact with an aspartate in the RT-loop of the c-Src SH3 domain (22). 
These observations suggest that VSL12 may bind SFK SH3 domains with similar potency, 
thereby representing a useful ligand to probe the role of the SH3 domain in kinase regulation 
across the Src family. 
The amino acid sequence of VSL12 is aligned with the SH2-kinase linker of c-Src in 
Figure 13A, and structural models of the c-Src SH3 domain bound to VSL12 vs. its own SH2-
kinase linker are presented in Figure 13B. Comparison of these structures reveals that VSL12 
forms a much more extensive interface with the SH3 domain compared to the natural linker. 
Proline residues at VSL12 positions 12 and 9, together with adjacent leucine residues (L11 and 
L8), occupy grooves formed by conserved SH3 domain residues Y90, Y92, W118, and Y136 
(see Figure 5 for SH3 domain alignment).  
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Figure 13. Interaction of the VSL12 peptide with the SH3 domain of c-Src 
A) Comparison of the sequence of the SH3-binding peptide VSL12 (top) with that of the c-Src SH2-kinase linker 
(bottom). Note that prolines occupy the critical P0 and P+3 positions of the PPII helix in VSL12, which intercalate 
into the aromatic binding grooves of the SH3 surface. The Src linker, by contrast, has a single proline at P0 and 
glutamine at P+3. Note that the VSL12 sequence is presented in the C- to N-terminal orientation relative to the 
linker. B) Comparison of the c-Src interaction with the VSL12 peptide and the SH3-kinase linker. The NMR 
solution structure of the Src SH3 domain (red) with the VSL12 peptide (cyan) is modeled on the left (PDB: 1QWF) 
(22). The side chains of the SH3 domain residues that interact with VSL12 are shown in green (Y90, Y92, Y136 and 
W118), and interacting VSL12 side chains are shown in cyan (P12, L11, P9, and L8). The salt bridge between 
VSL12 R6 and SH3 D99 is also shown. The analogous interaction of the Src SH3 domain with the SH2-kinase 
linker from the inactive structure of c-Src is shown on the right (PDB: 2SRC) (6). Linker residue P250 contributes to 
this interaction in the P0 position, while Q253 occupies the P+3 position and is rotated away from the SH3 surface. 
The position of K257 is also shown; it does not contact D99 in this structure.  
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In addition, VSL12 has an arginine residue in position 6, which forms a salt bridge with D99 in 
the Src SH3 domain; aspartate is found at this position all SFK SH3 domains as well (Figure 5). 
By comparison, the c-Src SH2-kinase linker forms fewer contacts with the SH3 domain in the 
context of the overall downregulated structure of c-Src. While the linker does form a PPII helix, 
only one proline is present in the sequence (P250) and packs between SH3 Y90 and Y136 in a 
similar position as P12 in the SH3:VSL12 peptide structure (P0 position; Figure 13B). However, 
Q253 occupies the P+3 position, normally occupied by proline in high-affinity SH3 ligands (P9 
in VSL12). The long polar side chain of Q253 is too bulky to fit in the pocket formed by SH3 
Y92, W118, and Y136, and points away from the SH3 domain. While a basic residue (K257) is 
present near the C-terminal end of the linker SH3-binding sequence, it does not form a salt 
bridge with the conserved aspartate (D99) in the SH3 domain. These observations suggest that 
the linker sequence represents a suboptimal SH3 ligand, and that VSL12 may be able to compete 
with the linker for SH3 binding. 
2.3.2 The VSL12 peptide binds SFK SH3 domains with similar affinity and competes with 
the linker for near-full-length kinase binding.  
We first measured the affinity of the isolated SFK SH3 domains for the VSL12 peptide using 
surface plasmon resonance (SPR). For these experiments, VSL12 was immobilized on a 
biosensor chip, and the recombinant SH3 domains were flowed past the peptide as described 
under Materials and Methods. Surface densities were kept low to ensure that binding conformed 
to a 1:1 Langmuir interaction. Sensorgrams for the interaction of the SFK SH3 domain to the 
VSL12 peptide-coated surface are shown in Figure 14.  
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Figure 14. VSL12 binds to SH3 domains and near-full length SFK-YEEI proteins by SPR 
Surface plasmon resonance (SPR) was used to evaluate VSL12 peptide binding kinetics and affinity for the isolated 
SFK SH3 domains (left) as well as near-full-length SFK-YEEI proteins (right). The biotinylated peptide was 
immobilized to 80 Response Units (RU) on the surface of a streptavidin (SA) biosensor chip. The recombinant 
purified SH3 and SFK-YEEI proteins were flowed over the peptide over the concentration ranges shown. 
Association was measured for 180 s, followed by a 300 s dissociation phase. Each panel shows a representative 
sensorgram, with the double-referenced binding data (black trace) fit to a 1:1 Langmuir binding model (red trace). 
Kinetic constants derived from this experiment are presented in Table 3. The VSL12 peptide binds with similar 
affinities to near-full-length Src-family kinases and their isolated SH3 domains.  
 
All four SH3 domains bound to VSL12 in a concentration-dependent manner with rapid on-rates, 
and showed complete dissociation from the peptide following washout. Table 3 summarizes the 
resulting association (ka) and dissociation (kd) constants as well as the equilibrium dissociation 
constants derived from them (KD). All four SH3 domains bound to VSL12 with low micromolar 
affinities, consistent with previously published values for the c-Src and Hck SH3 domains (166, 
171). 
We next explored the binding of recombinant, purified near-full-length Src-family kinase 
proteins to VSL12 using the same approach (Figure 14). For these studies, we used purified 
recombinant SFK proteins in which the natural C-terminal tails were replaced with the sequence 
pTyr-Glu-Glu-Ile-Pro (referred to hereafter as SFK-YEEI proteins). This tail modification 
creates an optimal SH2-binding sequence and has been used in previous structural and enzymatic 
studies to ensure downregulation of kinase activity through enhanced binding of the tail to the 
SH2 domain in the absence of Csk co-expression (32, 96). Surprisingly, each of the near-full-
length SFKs bound to VSL12 with low nanomolar affinity. Comparison of the ka values for the 
 58 
SFKs with those for the isolated SH3 domains shows nearly identical association constants for 
the two sets of proteins (Table 3).  
Table 3. Kinetic Constants for SH3 Domains and Near-Full-Length SFKs for the VSL12 Peptide Measured 
by Surface Plasmon Resonance 
Protein ka (M
-1
s
-1
) kd (s
-1
) KD (M) χ
2
 
Src SH3
a
 1.21 × 10
5
 4.14 × 10
-1
 3.42 × 10
-6
 0.570 
Fyn SH3
b
 1.06 × 10
6
 3.72 × 10
-1
 3.51 × 10
-7
 1.890 
Hck SH3
c
 7.88 × 10
4
 2.17 × 10
-1
 2.76 × 10
-6
 1.360 
Lyn SH3
b
 2.12 × 10
5
 1.37 × 10
-1
 6.47 × 10
-7
 1.850 
Src-YEEI
d
 1.57 × 10
5
 6.33 × 10
-4
 4.03 × 10
-9
 0.374 
Fyn-YEEI
e
 5.39 × 10
4
 5.53 × 10-
4
 1.03 × 10
-8
 0.765 
Hck-YEEI
f
 7.13 × 10
4
 4.54 × 10
-4
 6.36 × 10
-9
 0.667 
Lyn-YEEI
d
 1.05 × 10
5
 8.71 × 10
-4
 8.28 × 10
-9
 0.567 
Hck-YEEI
c,g
 1.12 × 10
4
 5.49 × 10
-4
 4.90 × 10
-8
 0.126 
a
 31.25, 62.5, 125, 250, 500, 1000 nM  
b
 31.25, 62.5, 125, 250 nM 
c
 31.25, 62.5, 125, 250, 500 nM 
d
 7.81, 15.62, 31.25, 62.5 nM 
e
 0.98, 1.95, 3.9, 7.81, 15.62, 31.25 nM 
f
 7.81, 31.25, 62.5, 125 nM 
g 
This analysis was performed with a lower amount of VSL12 peptide immobilized on the SA chip surface to rule 
out re-binding artifacts (25 RU rather than 80 RU). 
 
SPR analysis was performed with biotinylated VSL12 peptide bound to a streptavidin biosensor chip as described 
under Materials and Methods. Each protein was flowed past the chip surface over the concentration ranges indicated 
in the footnotes. Duplicate runs were performed for each concentration. A control cycle of buffer only was 
subtracted from all concentrations of reference-subtracted curves. Interaction data were curve-fit using a 1:1 binding 
model, and the kinetic constants and chi-square values were calculated using BIAevaluation software (v. 4.1.1). 
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However, the kd values for the SFK proteins are roughly 1000-fold lower than for the 
SH3 domains, suggesting that VSL12 binding induces a stabile kinase-peptide complex. To 
exclude the possibility that this lower dissociation rate constant results from rebinding events 
during the dissociation phase, an additional SPR experiment was conducted using the minimum 
surface level of VSL12 peptide required for kinetic analysis (25 response units) to determine the 
KD for Hck-YEEI. The resulting ka, kd, and KD values were similar to those generated on the 
higher surface level of VSL12 (Table 3). These SPR results show that the VSL12 peptide binds 
with similar kinetics to each Src-family member, and is a suitable ligand to test for SH3-based 
activation of each kinase by SH3 domain displacement. 
2.3.3 Characterization of recombinant SFK-YEEI protein kinase activity in vitro.  
In order to characterize the sensitivity of individual SFKs to SH3-based activation, we initiated 
kinetic kinase assays with each of the recombinant SFK-YEEI proteins in the presence of the 
SH3-binding peptide, VSL12. As described in the preceding section, the YEEI tail modification 
allows for purification of each Src-family member in the downregulated state. In addition, the 
increased affinity of the tyrosine-phosphorylated YEEI tail for the SH2 domain ensured that 
kinase activation observed in response to VSL12 binding can be attributed to the displacement of 
the SH3 domain rather than complete disruption of the regulatory apparatus.  
Prior to testing for SH3-based kinase activation using the VSL12 peptide, uniform assay 
conditions were established for each SFK. We first determined the Km values for both ATP and 
the peptide substrate, YIYGSFK, for all four of the SFK-YEEI proteins using a kinetic assay. As 
shown in Figure 15, all of the SFKs obey Michaelis-Menten kinetics for both ATP and the 
peptide substrate. Table 4 summarizes the Km values determined for each kinase.  
 60 
 
 
 61 
Figure 15. Recombinant near-full-length Src-family kinases obey Michaelis-Menten kinetics. 
Initial reaction velocities for each of the SFK-YEEI proteins shown were determined over a range of ATP and 
peptide substrate (sequence YIYGSFK) concentrations as described under Materials and Methods. Plots of reaction 
velocity vs. the concentration of ATP (left panels) and substrate (right panels) exhibited saturation kinetics and were 
fit to the Michaelis-Menten equation by non-linear regression analysis (GraphPad Prism Software). The resulting Km 
and Vmax values are presented in Table 4. 
 
Table 4. Km Values for ATP and Peptide Substrate for Near-Full-Length SFKs 
Kinase ATP (µM) YIYGSFK (µM) 
Src-YEEI 67.0 ± 10.3 159.1 ± 20.9 
Fyn-YEEI 49.7 ± 8.2 69.6 ± 3.7 
Hck-YEEI 55.8 ± 18.5 83.8 ± 12.5 
Lyn-YEEI 31.1 ± 9.70 83.2 ± 4.9 
 
The Km values for ATP and the substrate peptide, YIYGSFK, were determined for each SFK-YEEI protein using the 
ADP Quest assay as described under Materials and Methods. ATP experiments were performed three times for each 
kinase and substrate experiments were performed four times for each kinase, except for Src-YEEI, where ATP 
experiments were performed twice and substrate experiments were performed three times. Mean values are shown 
for each kinetic constant ± S.E.  
 
All four Src-family members showed very similar Km values for ATP, ranging from 31 to 
67 µM. These values are in the same range as those reported previously for these kinases, despite 
the use of different assay methods (29-31). Km values for the substrate peptide also varied by 
about two-fold, with Src-YEEI exhibiting the highest value (159 µM) and Fyn-YEEI the lowest 
(70 µM). To control for inherent variations in substrate utilization by each Src-family member, 
all subsequent experiments were done with the ATP and peptide substrate concentrations set to 
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the respective Km values for each kinase. Finally, kinase titrations were performed to determine 
enzyme concentrations that yielded a basal rate of about 1 pmol ADP produced/min. Figure 16 
shows the production of ADP over time for a range of six Src-YEEI concentrations.  
 
Figure 16. Time course of ADP production for a concentration range of Src-YEEI 
Representative time course of ADP production for six concentrations of Src-YEEI. At higher kinase concentrations, 
the reaction rates plateau as the fluorescence reading reaches saturation. The linear portion of each curve was fit by 
linear regression analysis to provide the slope, which corresponds to the rate of the reaction in pmol ADP 
produced/min.  
 
The reaction rate increases as a function of kinase concentration, as reflected in the 
increase in the slope of the linear portion of the curve for each kinase concentration. Reaction 
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rates were determined in the same way for the remaining SFK-YEEI proteins, and the results are 
shown in Figure 17.  
 
 
Figure 17. Linear relationship between SFK-YEEI activity and input kinase 
Reaction rates for each SFK-YEEI protein are plotted against input kinase concentration. Curves were best-fit by 
linear regression analysis (dotted lines) and used to estimate the basal reaction rate for each kinase.  
 
All four kinases showed a linear relationship between input kinase amount and reaction 
velocity over the range of kinase concentrations tested. Because the specific kinase activity 
differs for each family member, these experiments allowed us to identify input kinase amounts 
that yielded equivalent basal rates for subsequent SH3 domain-displacement experiments with 
VSL12.  
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2.3.4 Differential sensitivity of Src-family members to activation by VSL12 peptide 
binding.  
We next tested the susceptibility of each Src-family member to SH3-based activation using the 
VSL12 peptide as an SH3 domain ‘agonist’. Using the established conditions for substrate, ATP, 
and kinase concentration as described above, the VSL12 peptide was titrated into the assay over 
a concentration range of 0.1 to 300 M. Figure 18A shows the reaction velocity for each kinase 
as a function of VSL12 peptide concentration. These data show that all four Src-family members 
are susceptible to activation by the VSL12 peptide, providing strong evidence that SH3:linker 
interaction has an important role in kinase regulation across the entire Src family. 
 
Data presented in Figure 18A demonstrate that the extent of kinase activation is saturable at 
higher concentrations of the VSL12 peptide. These data were therefore fit to Equation 1 to 
determine the Vmax for each kinase reaction as a measure of the highest level of SH3-dependent 
activation attainable for each kinase. Figure 18B compares the basal reaction rate to the Vmax for 
each kinase in the presence of VSL12. This analysis revealed that Src-family kinases have 
remarkably different responses to SH3-based kinase activation. Lyn-YEEI showed the smallest 
response, with a Vmax of about 5 pmol ADP produced/min, while Hck-YEEI showed a much 
higher response, approaching 30 pmol ADP produced/min. Fyn-YEEI and Src-YEEI exhibited 
intermediate responses with values of 11 and 16 pmol ADP produced/min, respectively. These 
results support the idea that individual Src-family members have very different inherent 
enzymatic capacities, at least in response to SH3 domain-based activation. 
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Figure 18. Differential sensitivity of individual SFK-YEEI proteins to activation by SH3 domain displacement 
Each of the SFK-YEEI proteins shown was assayed in the presence of VSL12 over a range of 
concentrations (0.1 to 300 µM). ATP and substrate concentrations were set to the Km for each kinase, and input 
kinase concentrations were set to achieve a basal reaction velocity of 1 pmol ADP produced/min. A) Each of the 
kinases is activated by VSL12 in a concentration-dependent manner. Plots of reaction velocity vs. VSL12 
concentration were best-fit by the Michaelis-Menten equation, allowing for the determination of the Vmax. Each data 
point was assayed in triplicate and is shown as the mean ± S.E. B) Comparison of basal rate (left) and Vmax (right) 
for each kinase in the presence of VSL12. Bars heights correspond to the mean values from triplicate experiments ± 
S.E. 
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In addition to defining the extent to which each kinase can be activated by VSL12 (Vmax), 
we also calculated an activation constant (Kact) for each kinase in response to this SH3-binding 
peptide. Kact defines the concentration of VSL12 required to increase the reaction rate to one-half 
of the Vmax, and is calculated by subtracting the basal kinase activity (without VSL12) from the 
reaction rate observed at each VSL12 concentration and performing nonlinear regression 
analysis using Equation 2 (see Materials and Methods). As shown in Table 5, the Kact values for 
VSL12-based activation of Src-YEEI, Fyn-YEEI, and Hck-YEEI were all remarkably similar 
(22-25 µM). In contrast, Lyn-YEEI displayed a lower Kact compared to the other kinases (4 M), 
which may suggest higher sensitivity to activation by SH3 domain displacement, although the 
maximum response observed was the lowest among the four kinases tested. Interestingly, Lyn 
and Hck are the most closely related among the SFKs tested in terms of phylogeny, yet their 
sensitivity to VSL12-induced activation is the most diverse. 
 
Table 5. Basal Rate, Maximal Velocity, and Activation Constants for VSL12 with each SFK 
Kinase 
Basal reaction velocity
 
(pmol ADP 
produced/min) 
Vmax 
(pmol ADP 
produced/min) 
Kact 
(µM) 
Src-YEEI 1.27 ± 0.08 15.77 ± 0.67 22.42 ± 2.23 
Fyn-YEEI 1.22 ± 0.10 11.41 ± 0.55 24.95 ± 1.91 
Hck-YEEI 1.97 ± 0.14 27.94 ± 1.02 22.38 ± 2.18 
Lyn-YEEI 0.93 ± 0.20 5.00 ± 0.24 4.03 ± 0.61 
 
The basal reaction velocity, maximum velocity (Vmax), and activation constant (Kact) were determined for each 
kinase in the ADP Quest assay as described under Materials and Methods. Basal velocity is the rate of kinase 
activation in the absence of the VSL12 peptide. Kinetic constants were determined in triplicate and are presented as 
the mean ± S.E. 
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2.3.5 Hck and c-Src remain susceptible to activation by SH3 domain displacement after 
autophosphorylation.  
In addition to regulatory domain engagement, SFK activity is also regulated by the 
phosphorylation state of the kinase domain activation loop (Figure 1). However, whether or not 
activation loop phosphorylation results in maximal kinase activation or whether the 
autophosphorylated kinase is still susceptible to further activation by SH3 domain displacement 
is not known. To explore this question, we focused on c-Src and Hck, because these are the only 
two family members for which the crystal structures of their downregulated states are known. 
Before examining the impact of VSL12 binding on SFK activity as a function of 
autophosphorylation, we first confirmed that the activation loops of recombinant Hck-YEEI and 
Src-YEEI were not phosphorylated prior to addition to the assay. To do this, the recombinant 
purified kinases were digested with pepsin and the phosphorylation states of the activation loop 
and tail tyrosines were determined by mass spectrometry. As shown in Figure 19, the C-terminal 
tail tyrosines are phosphorylated in both Src-YEEI and Hck-YEEI as expected for the inactive 
conformations, while no activation loop tyrosine phosphorylation was detected in either case.  
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Figure 19. Mass spectrometric analysis of Src-YEEI and Hck-YEEI tail and activation loop tyrosine 
phosphorylation.  
A) ESI-MS/MS spectra of Src-YEEI peptic peptide YFTSTESQpY
527
EEIP ([M+H]
+
 = 1683.68 Da), which is 
derived from the C-terminal tail, indicates that Tyr527 is phosphorylated (numbering as per crystal structure of c-
Src; PDB ID: 2SRC). The mass difference between fragment ions b8 and b9 (blue) indicates the presence of a 
phosphate group attached to the tyrosine residue (243 Da). The y ions are colored in red. B) ESI-MS/MS spectra of 
Src-YEEI peptic peptide Y
416
TARQGAKF ([M+H]
+
 = 1041.54 Da), which maps to the activation loop in the kinase 
domain, indicates that Tyr416 is not phosphorylated (163 Da). The mass difference between fragment ions y8 and y9 
(red) corresponds to the unphosphorylated tyrosine. C) ESI-MS/MS spectra of Hck-YEEI peptic peptide 
ESQpY
527
EEIP ([M+H]
+
 = 1074.40 Da), derived from the C-terminal tail, indicates that Tyr527 is phosphorylated. 
The mass difference between fragment ions b3 and b4 (blue) indicates the presence of a phosphate group attached to 
the tyrosine residue. D) ESI-MS/MS spectra of the Hck-YEEI peptic peptide Y
416
TAREGAKF ([M+H]
+
 = 1042.54 
Da), derived from the activation loop, indicates that Tyr416 is not phosphorylated. The mass difference between 
fragment ions y8 and y9 (red) corresponds to the unphosphorylated tyrosine. 
 
To test whether Src-YEEI and Hck-YEEI can be activated further by SH3 domain 
displacement after activation loop autophosphorylation, both kinases were preincubated in the 
presence or absence of ATP prior to testing for sensitivity to activation by VSL12. Time-course 
experiments in a kinetic kinase assay revealed that kinase autophosphorylation reached a plateau 
after three hours of incubation with ATP (data not shown), so preincubation was conducted for 
this time period prior to assessment of the VSL12-induced response. In both cases, the basal rate 
of kinase activity (no VSL12) was dramatically increased after pre-incubation with ATP. For 
Src-YEEI, the basal rate increased from 1.74 pmol ADP produced/min in the absence of ATP to 
6.38 in the presence of ATP following the preincubation step. Similarly, the basal rate of Hck-
YEEI activation increased from 1.27 to 9.04 pmol ADP produced/min following preincubation 
with ATP. This increase is presumably due to autophosphorylation of the activation loop tyrosine 
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and stabilization of the active site conformation. Note that the basal rate of each kinase following 
preincubation in the absence of ATP is consistent with the basal rates shown in Figure 18B and 
Table 5, indicating that the preincubation step did not compromise basal kinase activity. 
Figure 20 shows the effect of SH3 domain displacement by VSL12 on Src-YEEI and 
Hck-YEEI activity as a function of autophosphorylation. In each case, the basal rate observed in 
the absence of VSL12 was subtracted from the rate at each peptide concentration to reveal 
additional activation resulting from VSL12 binding to the SH3 domain.  
Autophosphorylated Src-YEEI and Hck-YEEI were both activated by VSL12 in a 
concentration-dependent manner, demonstrating that phosphorylation of the activation loop does 
not uncouple the kinase domain from the regulatory influence of the SH3 domain. However, we 
observed remarkable differences in the responses of Src-YEEI vs. Hck-YEEI to VSL12 
following pre-incubation with ATP. The curves for Hck-YEEI activation by VSL12 were 
identical, whether the kinase was preincubated with ATP or not. This observation suggests that 
activation of Hck-YEEI by SH3 domain displacement is independent of activation loop 
phosphorylation. Conversely, preincubation of Src-YEEI with ATP enhanced the response to 
VSL12, indicating that autophosphorylation of Src-YEEI sensitizes the kinase domain to further 
activation by SH3 domain displacement. These differences suggest that c-Src and Hck may have 
evolved to respond to different types of cellular inputs for activation and have important 
implications for signaling. 
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Figure 20. Src-YEEI and Hck-YEEI retain sensitivity to activation by SH3 domain displacement after 
autophosphorylation. 
Src-YEEI (A) and Hck-YEEI (B) were incubated in the absence or presence of ATP (at the Km) for 3 hours at 25 °C 
to induce autophosphorylation of Tyr416 in the activation loop. The autophosphorylated kinases were then assayed 
for responsiveness to the SH3-binding peptide, VSL12. The basal reaction velocity (no VSL12) was subtracted from 
the rate at each VSL12 concentration, and the resulting linear reaction velocities were plotted as a function of 
VSL12 concentration as shown. Each data point was assayed in triplicate and the average value is plotted ± S.E. 
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2.4 DISCUSSION 
The mechanisms responsible for SFK downregulation have been established by extensive 
biochemical and structural studies and appear to be conserved among all family members. The 
precise mechanisms of kinase activation, and whether or not they are also conserved across this 
kinase family, are less clear. Displacement of intramolecular regulatory interactions involving 
the SH2 and/or SH3 domains can cause kinase activation, suggesting that individual family 
members may be finely tuned to respond to inputs through their regulatory domains in specific 
ways. In this study, we provide direct evidence in support of this idea. Using a peptide ligand 
(VSL12) to induce kinase activation by SH3 domain displacement, we showed a wide range of 
sensitivities to this allosteric activation mechanism across the Src kinase family. Furthermore, we 
observed that c-Src becomes more susceptible to activation by SH3 domain displacement after 
autophosphorylation of the activation loop tyrosine. In contrast, activation of Hck through its 
SH3 domain was independent of kinase domain autophosphorylation, revealing a very different 
response to this activating input despite the remarkable similarity to c-Src in terms of the 
structure of the inactive state (6, 31, 32, 155). 
We chose the VSL12 peptide as the SH3 ligand for these studies because previous work 
showed that it binds to the c-Src, Fyn, and Lyn SH3 domains with similar micromolar affinities 
(19, 166). SPR results presented here show that VSL12 bound to the SH3 domains of these three 
SFKs as well as that of Hck with low micromolar dissociation constants, providing a useful 
peptide ligand to compare the effect of SH3 domain displacement on kinase activity across the 
kinase family. The solution structure of the Src SH3 domain in complex with VSL12 reveals the 
key SH3 residues that interact with the peptide that suggest a mechanism for linker displacement 
(22). The hydrophobic pocket formed by SH3 Y90 and Y136 is occupied by the lone proline 
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residue in the Src SH2-kinase linker (P250; Figure 13B). This interaction is likely displaced by 
VSL12 L11 and P12 which occupy the same pocket in the NMR structure. In addition, VSL12 
L8 and P9 both make contacts with the SH3 domain, while the analogous positions are occupied 
by T252 and Q253 in the linker; Q253 does not contact the SH3 domain in the inactive c-Src 
structure (Figure 13B). Furthermore, VSL12 R6 forms a stabilizing ionic contact with conserved 
SH3 D99, and also makes a hydrogen bond with the side chain of W118. This interaction is 
missing in the SH3:linker interface in downregulated c-Src. The SH3 domain residues involved 
in VSL12 binding are conserved across the four SFKs studied here, consistent with the 
similarities in binding kinetics and affinities observed by SPR (Table 3). 
In addition to the isolated SH3 domains, we also determined the interaction of VSL12 
with the corresponding downregulated, near-full-length SFK proteins by SPR for the first time. 
In this case, we anticipated a lower apparent affinity of VSL12 for the SH3 domain in the context 
of the near-full-length kinase, because of competition with the linker. Such a phenomenon has 
been reported previously for the interaction of HIV-1 Nef with Hck, which exhibits a higher 
affinity for the isolated SH3 domain vs. the near-full length kinase (98, 157). Instead, we 
observed much higher affinity of VSL12 for all four near-full-length kinases, with equilibrium 
dissociation constants in the low nanomolar range. While the kinetic association constants for the 
individual SH3 domains and SFK-YEEI proteins were similar, the dissociation constants for the 
SFK-YEEI protein were roughly 1000-fold lower. These observations suggest that the 
SH3:VSL12 complex may be stabilized in the near-full-length kinase through additional 
interactions, possibly with the N-lobe of the kinase domain or with the displaced linker itself. 
Identification of residues that stabilize the VSL12 interaction with the near-full-length kinase 
may guide the future development of Src-family kinase agonists.  
 74 
Work presented here supports the idea that Src-family kinases are generally susceptible to 
activation by SH3 domain displacement. In addition, VSL12-based activation of recombinant 
SFK proteins with YEEI tails shows that disruption of SH2:tail interaction is not required for 
SH3-based activation, as the pYEEI sequence has a much higher affinity for the SH2 domain 
than the natural tail sequence (32, 172). While the VSL12 peptide bound to and activated all of 
the kinases, differences in the extent of activation were striking. Particularly surprising was the 
difference in sensitivity to SH3-based activation between Hck and Lyn, as they are the most 
similar in amino acid sequence among the entire Src kinase family. Our observation that Hck and 
Lyn demonstrate very different responses to SH3-based activation by VSL12 is consistent with 
previous reports with the Nef protein of HIV-1. Like VSL12, Nef binds to the SH3 domains of 
Hck and Lyn with similar affinity, yet Nef activates Hck more strongly both in vitro and in cell-
based assays (90, 173). One possibility is that maximal activation of Lyn may also require 
displacement of the C-terminal tail from the SH2 domain, which does not appear to be the case 
for Hck. 
To understand how interaction with VSL12 induces kinase activation, the structures of 
Src-family kinases in the active vs. inactive conformations must be considered. In the 
downregulated structure of c-Src, the SH3 domain contacts both the SH2-kinase linker (as 
described above) and R318 in the N-lobe of the kinase domain through D117. Additionally, a 
key residue that has been shown to couple the SH3-SH2 region of the protein to the kinase 
domain is W260 at the C-terminal end of the linker (163). In the inactive conformation, 
conserved W260 packs against helix C, helping to position it away from the active site and 
preventing formation of a salt bridge between E310 and K295 that is required for kinase activity. 
Because VSL12 has a relatively high affinity for the SH3 domains of the SFKs, it is likely to 
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bind to the SH3 domain, displace the linker and shift W260 away from the C helix. The 
stabilizing interaction between SH3 domain D117 and N-lobe R318 may also be disrupted as a 
consequence. Removal of these inhibitory constraints would allow the C helix to rotate inward, 
with E310 forming the critical salt bridge with K295. This rearrangement also exposes activation 
loop Y416 for autophosphorylation. By analogy to the active structure of the Lck kinase domain 
(34), phosphorylation of Y416 is anticipated to result in an intrastrand ionic contact with R409. 
This interaction stabilizes the active conformation of the conserved DFG motif at the N-terminal 
end of the activation loop and is essential for phosphate binding and catalysis.  
Another remarkable difference between the SFKs relates to the coupling of activation 
loop autophosphorylation and sensitivity to SH3 domain displacement. Autophosphorylation of 
Y416 strongly stimulated both Hck and c-Src kinase activity in the absence of the VSL12 
peptide. In addition, both kinases were further activated by VSL12 in a concentration-dependent 
manner, demonstrating that activation loop phosphorylation enhances kinase activity 
independently of regulatory domain displacement. This observation suggests that Y416 
phosphorylation alone is sufficient to reorganize the active site for phosphotransfer. However, 
our data show that autophosphorylation alone does not maximally increase kinase activity, 
because addition of VSL12 enhanced both c-Src and Hck kinase activity to an even greater 
extent. The additional impact of this SH3 domain ligand on autophosphorylated SFKs implies 
that displacement of the SH3 domain relieves additional allosteric constraints on the kinase 
domain, possibly through W260 or direct SH3 interaction with the N-lobe as described above. 
Furthermore, this observation implies that autophosphorylation of the activation loop does not 
cause release of the SH3 domain from the linker, at least for c-Src and Hck. 
 76 
Our finding that autophosphorylated c-Src and Hck are still under the allosteric control of 
the SH3 domain is consistent with recent studies of c-Abl kinases. Like SFKs, the c-Abl kinase 
‘core’ consists of a similar arrangement of SH3 and SH2 domains, an SH2-kinase linker, 
followed by the kinase domain. In this system, intramolecular interaction of the SH3 domain 
with the linker is also essential for downregulation of Abl kinase activity (174). Interestingly, 
active mutants of c-Abl, as well as the constitutively active Bcr-Abl fusion protein associated 
with chronic myelogenous leukemia, are both sensitive to linker proline substitutions that 
enhance interaction with the SH3 domain (175). Together with our data, these observations 
support the idea that activation loop phosphorylation and regulatory domain displacement 
represent independent modes of SFK and Abl regulation.  
While activation of Hck-YEEI by VSL12 binding was not enhanced by 
autophosphorylation, Src-YEEI was primed for further activation by VSL12 upon preincubation 
with ATP. This observation suggests distinct regulatory controls for each of these kinases, 
despite the fact that they are composed of the same component parts. These differences may have 
evolved to meet specific needs for kinase regulation under distinct physiological conditions. For 
example, c-Src is locally active in focal adhesions, where it regulates their turnover during cell 
adhesion and migration. One important mechanism of c-Src activation in focal contacts involves 
direct interaction with FAK. In this case, the SH3 and SH2 domains of c-Src interact with FAK, 
integrating the localization of c-Src to focal adhesions with kinase activation via regulatory 
domain displacement (66). This interaction juxtaposes the c-Src and FAK kinase domains, 
raising the possibility of direct phosphorylation of the c-Src activation loop by FAK (176). 
Maximal c-Src activation in focal adhesions may therefore require displacement of both 
regulatory domains plus trans-phosphorylation by another kinase, consistent with our findings. In 
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contrast, Hck is expressed primarily in cells of innate immunity and is activated by diverse 
upstream signals including hematopoietic cytokines and Fc receptors (177-180). In this case, 
receptor engagement with Hck through its SH3 and/or SH2 domains may be sufficient to induce 
a rapid and transient response, without the need for secondary phosphorylation on the activation 
loop. These intrinsic differences in the sensitivity of c-Src, Hck and other SFKs to activating 
signals may provide opportunities for discovery of selective small molecule probes of their 
functions. 
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3.0  IDENTIFICATION OF INHIBITORS SELECTIVE FOR C-SRC IN COMPLEX 
WITH THE FAK SH3-SH2-BINDING REGION 
3.1 INTRODUCTION 
The c-Src protein-tyrosine kinase is the prototype of the Src kinase family and is broadly 
expressed in virtually every mammalian cell type (156). The domain organization of c-Src is 
shared by all eight mammalian Src-family kinases (SFKs; Figure 21A). At the N-terminus is a 
signal sequence for myristoylation, which targets c-Src to the cell membrane. Membrane 
association facilitates interactions of c-Src with binding partners such as receptor tyrosine 
kinases (RTKs) and is essential for function (7). The myristoylation signal is followed by a 
unique domain, which contains the most divergent sequences among the kinase family. C-
terminal to the unique region are the modular SH3 and SH2 domains, which bind to polyproline-
rich and phosphotyrosine-containing sequences, respectively. The SH3 and SH2 domains are 
important for interactions with other cellular proteins as well as kinase regulation. These 
domains are followed by an SH2-kinase linker, the kinase domain, and a C-terminal tail with a 
conserved tyrosine residue essential for negative regulation of kinase activity.  
SFKs maintain their inactive state through two intramolecular interactions involving the 
SH2 and SH3 domains. The SH3 domain interacts with a polyproline type II helix formed by the 
SH2-kinase linker while the SH2 domain binds to the tyrosine-phosphorylated tail (153). Tail 
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phosphorylation is mediated by the independent regulatory kinase Csk as well as the related 
kinase, Chk (154, 181). Both interactions are present in the x-ray crystal structure of c-Src in the 
downregulated conformation, shown in Figure 1 (6). 
 
Figure 21. Domain organization of c-Src and FAK 
A) The modular domain organization of c-Src is shown, which corresponds to the x-ray crystal structure of the 
downregulated conformation in Figure 1 (PDB ID: 2SRC). The conserved tyrosine residues in the activation loop 
(Y416) and the tail (pY527) are shown. Intramolecular interactions between the SH3 domain and the SH2-kinase 
linker as well as the SH2 domain and the tyrosine-phosphorylated tail are required to maintain the inactive state. The 
unique N-terminal domain and myristoylation site are not present in the crystallized protein. The domain 
organization of recombinant Src-YEEI used for this study is also shown, which lacks the N-terminal unique domain, 
and has the modified C-terminal tail sequence, YEEI. B) Modular domain organization of focal adhesion kinase 
(FAK) which consists of the N-terminal FERM domain (blue) the kinase domain (green), a proline-rich region 
containing SH3 binding sites for other focal adhesion proteins, and the C-terminal FAT domain (red). The linker 
connecting the FERM and kinase domains encompasses the binding site for c-Src, consisting of a PxxP motif (SH3 
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binding) and an autophosphorylation site in the sequence context pYAEI (SH2 binding). The sequence of the pFAK 
peptide used in the screening assay is also shown. 
 
Multiple mechanisms of SFK activation have been reported, including dephosphorylation 
of the C-terminal tail tyrosine, leading to the loss of the SH2:tail interaction (182), and 
displacement of one or both of the intramolecular interactions as a result of binding to peptides 
or other proteins (40, 171). Based on their sequences, the SH2-kinase linker and C-terminal tail 
represent low affinity ligands for their respective target domains. Displacement of these 
interactions by proteins with higher affinity for the SH3 and/or SH2 domains provides a 
mechanism for SFK activation by both physiological substrates as well as foreign proteins 
expressed as a result of microbial infection. For example, the Nef protein encoded by HIV-1 
binds to the SH3 domain of the Src-family member Hck, resulting in linker displacement and 
constitutive kinase activation. Alternatively, juxtamembrane autophosphorylation sites on active 
RTKs recruit c-Src through its SH2 domain, resulting in displacement of the tail and kinase 
activation. Other cellular protein partners for c-Src contain both SH3- and SH2-binding 
sequences to displace both intramolecular interactions, such as p130Cas (183) and the focal 
adhesion kinase (FAK) (66).  
FAK is a non-receptor protein tyrosine kinase that localizes to focal adhesions, the 
intracellular structures formed at sites of cell adhesion to the extracellular matrix (ECM). The 
domain organization of FAK consists of a protein 4.1/ezrin/radixin/moesin (FERM) domain, 
followed by high affinity binding sites for the c-Src SH3 and SH2 domains (Figure 21B) and the 
kinase domain. C-terminal to the kinase domain is a proline-rich region with binding sites for the 
SH3 domains of p130Cas and other proteins involved in the focal adhesion complex, followed 
by the focal adhesion targeting (FAT) domain that targets FAK to focal adhesions upon integrin 
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stimulation (103, 104, 184). Once recruited to focal adhesions, FAK autophosphorylates on 
Y397 creating a high-affinity binding site for the c-Src SH2 domain. Additionally, the c-Src SH3 
domain binds to a proline-rich sequence adjacent to the SH2 binding site. These tandem binding 
events displace both intramolecular regulatory interactions, leading to c-Src kinase activation. 
Once active, c-Src then phosphorylates FAK at multiple tyrosine residues. Two of these, pY576 
and pY577, localize to the activation loop of the kinase domain and are important for full FAK 
kinase activity. The others recruit SH2-containing proteins like p130Cas, which binds to pY861, 
and Grb2, which binds pY925 (113-115, 185). Coordinated activation of c-Src and FAK 
stimulates multiple signaling pathways linked to focal adhesion turnover and cell migration, an 
essential process in embryonic development, wound healing, and the immune response. Tight 
control of both c-Src and FAK activity is therefore very important for both cellular and tissue 
integrity. Indeed, cells lacking c-Src and FAK show a dramatically reduced rate of migration (51, 
121), while the hyperactivation of these kinases leads to an increased rate of migration that has 
been implicated in tumorigenesis.  
 Overexpression and increased activity of both c-Src and FAK has been reported in 
multiple tumor sites, including colon, head and neck, breast, and ovary (67-69, 186-191). 
Hyperactivation of the c-Src:FAK complex not only increases cell migration and invasion as a 
result of increased focal adhesion turnover, but also drives cell proliferation and survival (192, 
193). The recruitment of Grb2 to pY925 leads to the activation of the Ras pathway and 
stimulates cell proliferation. Additionally, the p85 subunit of phosphatidylinositol-3-kinase 
(PI3K) can bind to the pY397 site and lead to activation of Akt, which prevents apoptosis. 
The relationship of the c-Src:FAK complex to cancer progression highlights the potential for c-
Src and FAK as targets for cancer therapy (194-197). Multiple inhibitors of both c-Src and FAK 
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have been discovered and some have progressed into clinical trials. However, the success of 
these inhibitors, especially as monotherapy, has been limited (192, 198). One disadvantage of 
SFK inhibitors is their lack of selectivity for c-Src over other members of this kinase family. 
Kinase domain sequence and structural homology makes isoform-selective inhibitor targeting 
quite challenging. In this study, we approached this problem by developing a screening assay for 
inhibitors of c-Src in complex with the SH3-SH2-binding region of FAK. We hypothesized that 
binding of FAK to c-Src induces a unique active conformation that may be amenable to selective 
inhibitor targeting. In an effort to find a selective c-Src:FAK complex inhibitor, we identified in 
vitro kinase assay conditions such that the activation of c-Src was entirely dependent on the 
presence of a phosphopeptide based on the FAK SH3/SH2-binding sequences for c-Src. We then 
screened a kinase-biased inhibitor library and identified four compounds selective for the 
Src:FAK peptide complex versus Src alone. The most promising compound showed a five-fold 
preference for the active complex in both endpoint and kinetic kinase assays. Computational 
docking studies suggest that this compound prefers the ‘DFG-out’ conformation of the kinase 
active site, suggesting that binding of the pFAK peptide induces this kinase domain 
conformation. Our results provide an important proof-of-concept that state-selective ATP site 
inhibitors for c-Src can be identified under appropriate screening assay conditions. This approach 
may provide an additional avenue for inhibitor specificity in the context of large kinase families 
with highly homologous active sites. 
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3.2 MATERIALS AND METHODS 
3.2.1 Expression and purification of recombinant SFK-YEEI proteins.  
A human c-Src cDNA clone was modified on its C-terminal tail to encode the sequence 
Tyr-Glu-Glu-Ile-Pro (YEEI) as described previously for Hck (163). In addition, the N-terminal 
unique domain of c-Src was replaced with a hexa-histidine tag. The resulting sequence was used 
to produce a recombinant baculovirus in Sf9 insect cells using BaculoGold DNA and the 
manufacturer’s protocol (BD Pharmingen) as previously described (96). Src-YEEI was co-
expressed with the Yersinia pestis YopH phosphatase to promote dephosphorylation of the 
activation loop tyrosine to help downregulate kinase activity (164, 165). Sf9 cells were grown in 
monolayer and co-infected with Src-YEEI and YopH baculoviruses. Cells were harvested 72 h 
after infection for Src-YEEI purification as previously described (96). Purified Src-YEEI protein 
was stored in 20 mM Tris-HCl, pH 8.3, containing 100 mM NaCl. Kinase protein used in the 
Z’Lyte in vitro kinase assays also contained 3 mM DTT. The molecular weight of purified Src-
YEEI was confirmed by mass spectrometry and determined to be phosphorylated on the YEEI 
tail but not the activation loop, consistent with the structure of the downregulated conformation 
(6). 
3.2.2 Chemical library screen.  
A library of 586 kinase-biased inhibitors (199) was screened using the FRET-based 
Z’Lyte in vitro kinase assay and Tyr2 peptide substrate (Life Technologies) (200). Assays were 
performed in quadruplicate in 384-well low-volume nonbinding surface black polystyrene 
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microplates (Corning) according to the manufacturer’s instructions and as described previously 
(96, 199, 201). Briefly, the assay measures phosphorylation of the Tyr2 FRET-peptide substrate 
which is labeled with coumarin and fluorescein on its N- and C-terminii, respectively, which 
form a FRET pair. After the kinase reaction, a development step involves site-specific 
proteolytic cleavage of the unphosphorylated but not the phosphorylated peptide. Peptide 
cleavage results in loss of a FRET signal.  
Src-YEEI was first titrated into the assay over a concentration range of 0.5 – 500 ng/well 
(0.908 – 908 nM). Kinase activity was measured in the absence and presence of a 10-fold molar 
excess of the pFAK peptide with the sequence AAAARALPSIPKLANNEKQ-
GVRSHTVSVETDDYPAEIID (66) as well as the control peptides pYEEI (EPQYPEEIPIYL) 
(202), and VSL12 (VSLARRPLPPLP) (166). All peptides were synthesized by the University of 
Pittsburgh Genomics and Proteomics Core Laboratories and the mass and purity of each 
compound was confirmed by LC-MS. The kinase was pre-incubated with or without the peptides 
for 15 min, and the reaction was initiated by the addition of ATP (100 M) and Tyr2 peptide 
substrate (1 M). The kinase reaction was incubated 1 h, followed by addition of the 
development protease to cleave the unphosphorylated substrate. Coumarin and fluorescein 
fluorescence were measured 1 h later on a Molecular Devices SpectraMax M5 plate reader. 
Results are expressed as percent of maximum kinase activity relative to a stoichiometrically 
phosphorylated positive control peptide and negative control wells where no ATP is present. 
Screening assays were performed with Src-YEEI (30 ng) in the presence of a 10-fold molar 
excess of the pFAK peptide (545 nM pFAK to 54.5 nM Src-YEEI) or with Src-YEEI alone (125 
ng; 227 nM). These conditions yielded about 75% of maximum kinase activity in the absence of 
compounds. Each compound was assayed at a final concentration of 10 M with carrier solvent 
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(DMSO) at 2.5%. After peptide preincubation, the compound was added and incubated for 30 
minutes before initiating the kinase reaction.  The IC50 values for the hit compounds were 
determined over a concentration range of 3 nM to 30 M, and the resulting concentration-
response curves were best-fit by nonlinear regression analysis to obtain the compound IC50 
(GraphPad Prism). Results are expressed as percent inhibition, calculated relative to negative 
control wells without ATP (maximum inhibition) and DMSO only control wells (minimum 
inhibition).  
3.2.3 Kinetic Kinase Assays.  
The ADP Quest Assay (DiscoveRx) is a fluorescence-based assay used to monitor the 
production of ADP in kinase reactions (167). All assays were performed in quadruplicate in 
black 384-well microplates (Corning # 3571), in a final assay volume of 50 μl/well at 25°C as 
previously described (Chapter 2). ATP stocks were prepared in 10 mM Tris-HCl, pH 7.0, and the 
ATP concentration in each assay was held constant at 100 M. The SFK substrate peptide, 
YIYGSFK (Anaspec) (168) was prepared in ADP Quest assay buffer (15 mM HEPES, pH 7.4, 
20 mM NaCl, 1 mM EGTA, 0.02% Tween-20, 10 mM MgCl2, 0.1 mg/ml bovine γ-globulins). 
The substrate concentration in the assay was set to the Km value (162 M) determined 
previously (Chapter 2). In kinase inhibition assays, Src-YEEI concentration in the absence of 
peptide was 40 ng/well (14.5 nM) and in the presence of the peptide was 15.6 ng/well (5.7 nM). 
Kinase reactions were initiated by the addition of ATP. Assay plates were read every 5 min for 3 
h on a Molecular Devices SpectraMax M5 microplate reader. Results are expressed as percent of 
maximum kinase activity relative to the activity of the kinase in the absence of inhibitor.  
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3.3 RESULTS 
3.3.1 Development of a screening assay for Src:FAK selective inhibitors 
In order to screen for inhibitors selective for the c-Src:FAK kinase complex, we used a 
synthetic peptide based on the c-Src SH3 and SH2 binding sites from the FAK sequence, pFAK, 
to activate recombinant Src-YEEI. Our goal was to model the specific conformation of active c-
Src that results from interaction with FAK in focal adhesions. The pFAK peptide has been shown 
to bind to the tandem SH3-SH2 protein with low nanomolar affinity and to activate c-Src in vitro 
(66). 
 Before initiating the chemical library screen, we first established kinase assay conditions 
where recombinant Src-YEEI activity was dependent upon binding to the pFAK peptide. The 
Src-YEEI protein has a modified tail in which the wild-type sequence, Y527QPGENL, is 
replaced with YEEI to create a high affinity SH2-binding sequence. This modification allows the 
kinase to be purified in the downregulated state (32, 96). We first measured purified Src-YEEI 
activity over a range of kinase concentrations in the absence or presence of the pFAK peptide. 
As shown in Figure 22, the extent of substrate phosphorylation increased in sigmoidal fashion as 
a function of input kinase concentration, with an EC50 value of 151 ng in the absence of peptide. 
When this experiment was repeated in the presence of the pFAK peptide, the activation curve 
was shifted markedly to the left, yielding an EC50 value of 34 ng. This result is consistent with 
the interaction of the pFAK peptide with the Src-YEEI SH3 and SH2 domains, resulting in 
displacement of the regulatory apparatus from the back of the kinase domain and subsequent 
activation. 
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Figure 22. Activation of Src-YEEI by SH3- and SH2-binding peptides 
The activity of Src-YEEI was measured in the Z’Lyte in vitro kinase assay in the absence and presence of peptides 
that bind to the SH3 domain alone (VSL12), the SH2 domain alone (pYEEI), or to both (pFAK). Recombiant Src-
YEEI kinase protein was titrated into the assay over the range of 2-500 ng as shown, and peptides were added at a 
10-fold molar excess at each kinase concentration. The concentration of kinase that yielded 50% activation for each 
condition is shown (EC50). The arrow indicates the Src-YEEI concentration used in the screening assay, where Src-
YEEI activity is dependent on the pFAK peptide (30 ng kinase input). The sequences of the peptides are shown 
below the graph, and the docking sites for the Src SH3 and SH2 domains are indicated.  
 
To provide additional evidence that dual engagement of the SH3 and SH2 domains is necessary 
for maximal activation of Src-YEEI in our assay, we examined the effect of peptides that bind 
individually to the SH3 domain (VSL12) or the SH2 domain (pYEEI) on kinase activity. Both 
peptides activated Src-YEEI to a lesser extent than the pFAK peptide (Figure 22). The pYEEI 
peptide, which binds to the SH2 domain, decreased the EC50 value for Src-YEEI activation from 
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151 ng to 101 ng, while the VSL12 peptide, which exclusively engages the SH3 domain, 
decreased it to 68 ng. The finding that the VSL12 and pYEEI peptides do not activate Src-YEEI 
to the same extent as the pFAK peptide suggests that displacement of a single regulatory 
interaction is not sufficient for full kinase activation. The pFAK peptide, on the other hand, 
simultaneously displaces both of these interactions, presumably releasing all conformational 
constraints on the kinase domain. 
3.3.2 Identification of inhibitors selective for Src-YEEI in complex with the pFAK 
peptide 
 For inhibitor screening, we chose a concentration of Src-YEEI that was dependent on the 
pFAK peptide for activity so as to model the kinase conformation induced by FAK binding. As 
indicated by the arrow in Figure 22, roughly 30 ng of Src-YEEI alone was inactive in the assay, 
while addition of the pFAK peptide resulted in 40% of maximal activation. We also identified 
the concentration of Src-YEEI alone that resulted in the same level of activity (125 ng/well), 
which provided a basis of comparison in the screen. The ATP concentration was set to 100 M, 
which is in excess of published Km values for c-Src (203-205), and the substrate concentration 
was set to 1 μM. Using these assay conditions, we screened a kinase-biased small-molecule 
library (586 compounds) for preferential inhibitors of Src-YEEI in the presence of the pFAK 
peptide compared to Src-YEEI alone. Compounds were screened at a final concentration of 10 
M. The rank order of inhibitory potency for each compound is presented in Figure 23A, with  
the percent inhibition values shown in Table 7 (Appendix A).  
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Figure 23. Pilot screen for selective inhibitors of pFAK-dependent Src-YEEI activity 
A kinase-biased library of 586 compounds was screened for inhibitors of Src-YEEI activity in the presence of the 
pFAK peptide using the FRET-based Z’Lyte assay as described in the text. WH-4-124-2 is indicated in each graph 
by a red dot. WH-4-023 is indicated in each graph with a blue dot. A) Inhibitory activity for all compounds ranked 
by percent inhibition relative to the unphosphorylated substrate peptide control. Ninety-seven compounds inhibited 
kinase activity by at least 50% (dotted line). B) The Selectivity Ratio (SR) was calculated for the compounds 
showing greater than 50% inhibition of the Src-YEEI:pFAK complex in part A. This ratio was calculated as the 
percent inhibition of the Src-YEEI:pFAK complex divided by the percent inhibition observed with Src-YEEI alone. 
Twenty-four compounds exhibited a selectivity ratio greater than 3 (dotted line). 
 
The ninety-seven compounds that showed at least 50% inhibition of the complex were then 
assessed for inhibition of Src-YEEI alone. Results from these compounds were then ranked 
according to their selectivity ratio (SR), defined as: 
 
SR  =  % Inhibition of Src-YEEI:pFAK peptide complex 
                  % Inhibition of Src-YEEI alone 
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Twenty-four compounds with an SR greater than 3 (Figure 23B) were selected for further 
evaluation in concentration-response experiments. Of these, four compounds reproducibly 
inhibited Src-YEEI in the presence of the pFAK peptide to a greater extent than Src-YEEI alone 
(Figure 24 and 25A). The aminopyrimidinyl carbamate designated WH4-124-2 was chosen for 
further evaluation because it was the most potent and selective inhibitor of Src-YEEI in the 
presence of the pFAK peptide (Table 7, compound 543). As shown in Figure 25A and Table 6, 
this compound inhibited the Src-YEEI:pFAK peptide complex with an IC50 value of 0.88 μM in 
the Z’Lyte assay, as compared to 4.95 μM for Src-YEEI alone. 
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Figure 24. Inhibition of Selective inhibition of Src-YEEI by three compounds in the presence of the pFAK 
peptide 
HG-7-29-01, HG-7-47-01, and HG-7-128-01 were assayed against Src-YEEI alone (gray circles) and the Src-
YEEI:pFAK complex (black circles) over the range of inhibitor concentrations shown using the Z’Lyte assay. These 
inhibitors were selective for the complex in the primary screen and maintained selectivity in dose response 
experiments.   
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Figure 25. Selective inhibition of Src-YEEI by WH-4-124-2 in the presence of the pFAK peptide but not by 
the analog, WH-4-023 
WH-4-124-2 (A) and WH-4-023 (B) were assayed against Src-YEEI alone (gray circles) and the Src-YEEI:pFAK 
complex (black circles) over the range of inhibitor concentrations shown using the Z’Lyte assay. IC50 values were 
determined by curve-fitting and are shown in Table 6.  
 
3.3.3 WH-4-124-2 is a selective inhibitor of the Src-YEEI:pFAK complex 
 To further characterize the selective inhibitor WH-4-124-2, we first identified an analog 
of this compound with similar inhibitor potency for both Src-YEEI alone and in complex with 
the pFAK peptide. The compound WH-4-023 is very similar in structure to WH-4-124-2 (Figure 
25B) and inhibited both the complex and Src-YEEI alone by more than 70% in the screening 
assay (Table 7, compound 551). We then performed a concentration-response experiment with 
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this compound in the Z’-Lyte assay, and found that it inhibited Src-YEEI both alone and in 
complex with the pFAK peptide with an IC50 value of about 1.3 M. This result strongly 
suggests that the additional substituent present in WH-4-124-2 is responsible for inhibitor 
selectivity. 
  Selective inhibitor discovery and characterization described so far was performed using 
an end-point kinase assay, which does not provide direct information about the effect of either 
the activator peptide or the inhibitors on the kinase reaction rate. To further evaluate these 
compounds in a kinetic assay, we turned to the ADP Quest assay, which measures the progress 
of the kinase reaction as the accumulation of ADP. We began by performing a titration of Src-
YEEI activity in the absence and presence of the pFAK peptide to establish conditions for testing 
the compounds (Figure 26A). As in the Z’Lyte assay, we chose a concentration of Src-YEEI 
such that activation was dependent on the presence of the pFAK peptide (15.6 ng per reaction). 
The rate of activity at this concentration alone was barely detectable, with 0.2 pmol ADP 
produced per minute and increased to 1.0 pmol ADP/produced per minute in the presence of the 
pFAK peptide at a concentration of 30 M. To test for inhibition of Src-YEEI alone, we used 40 
ng kinase per reaction to achieve the same basal rate of 1.0 pmol ADP produced per minute.  
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Figure 26. WH-4-124-2 exhibits increased potency while maintaining selectivity in a kinetic kinase assay 
A) The activity of Src-YEEI was measured in the ADP Quest kinetic kinase assay in the absence (gray circles) and 
presence (black circles) of 30 M pFAK peptide. WH-4-124-2 (B) and WH-4-023 (C) were assayed against Src-
YEEI alone and the Src-YEEI:pFAK complex in the ADP Quest assay over the range of inhibitor concentrations 
shown. IC50 values were determined by curve-fitting and are shown in Table 6.  
 
Both WH-4-124-2 and WH-4-023 inhibited Src-YEEI activity in this assay in a concentration-
dependent manner (Figure 26B and C). As observed previously with the Z’Lyte assay, WH-4-
124-2 demonstrated selective inhibition of Src-YEEI in the presence of the pFAK peptide, while 
WH-4-023 did not. Table 6 compares the IC50 values generated in the ADP Quest assay for each 
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of these compounds to those from the Z’Lyte assay. WH-4-124-2 is more potent against Src-
YEEI in complex with the pFAK peptide than Src-YEEI alone with IC50 values of 114 vs. 531 
nM, respectively. By contrast, WH-4-023 inhibited Src-YEEI alone and the complex with very 
similar potencies, yielding IC50 values of 19 and 25 nM, respectively. While the IC50 values 
generated for both inhibitors in the ADP Quest assay are lower than those generated in the 
Z’Lyte assay, the relative selectivity for the Src-YEEI:pFAK complex is the same in both. This 
difference in apparent potency may be due to the different peptide substrates used in each assay, 
the ATP concentrations, or both. 
Table 6. IC50 values for kinase inhibitors WH-4-124-2 and WH-4-023 against Src-YEEI in the presence and 
absence of the pFAK peptide 
Compound  WH-4-124-2 WH-4-023 
Assay  Z’Lyte ADP Quest Z’Lyte ADP Quest 
Src-YEEI + pFAK  0.885 0.114 1.36 0.025 
Src-YEEI alone  4.95 0.531 1.28 0.019 
 
IC50 values (μM) were generated in the Z’Lyte endpoint assay used for the library screen and in the ADP Quest 
kinetic kinase assay for Src-YEEI in complex with the pFAK peptide vs. Src-YEEI alone.  
3.3.4 Docking studies of WH-4-124-2 with the c-Src and Lck kinase domains  
 Data presented in the previous sections suggest that binding of pFAK to c-Src may 
induce a conformation of the kinase active site that is stabilized by WH-4-124-2 binding. One 
well-known determinant of inhibitor specificity relates to the conformation of the highly 
conserved Aspartate-Phenylalanine-Glycine (‘DFG’) motif at the N-terminal end of the 
activation loop in the kinase active site (138, 206). In the active state, the aspartate in the DFG 
motif moves into the active site where it contributes to the coordination of ATP-Mg++. In the 
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inactive state, however, this aspartate residue moves away from the active site while the 
phenylalanine moves inward, resulting in the so-called ‘DFG-out’ conformation. Previous 
structural studies have shown that inhibitors such as imatinib prefer the DFG-out conformation 
of the Abl kinase domain, a therapeutically relevant target for this drug (135, 138). Interestingly, 
imatinib has also been co-crystallized with both c-Src and Lck, where it binds to a very similar 
DFG-out conformation (207, 208). These observations led us to consider whether WH-4-124-2 
may exhibit some of its selectivity by inhibiting a similar DFG-out state of the kinase domain.  
Comparison of the chemical structures of WH-4-124-2 and imatinib reveals significant 
overlap, allowing us to align the structure of WH-4-124-2 with imatinib in the X-ray crystal 
structure of the Lck kinase domain bound to this compound (Figure 27). This structure was 
chosen because all of its kinase domain features are resolved, including the activation loop and 
autophosphorylation site which are missing from the c-Src structure with imatinib. Figure 27 
shows imatinib bound to the Abl (A) and Lck (B) kinase domains, highlighting the positions of 
key active site features in the presence of imatinib. In these structures, the DFG motif is flipped 
outward. The Lck activation loop and tyrosine autophosphorylation site are extended outward, 
whereas in Abl the equivalent tyrosine is hydrogen-bonded to the catalytic aspartate. This 
comparison suggests that in Lck, imatinib traps a ‘primed’ or intermediate state between the 
downregulated and fully active forms of the kinase domain. WH-4-124-2 was then aligned with 
imatinib using the docking routine smina (209), a modified version of AutoDock Vina optimized 
for user-specified custom scoring functions (Figure 27C).  
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Figure 27. Computational docking of WH-4-124-2 to the x-ray crystal structure of the Lck kinase domain 
bound to imatinib. 
A) The active site of c-Abl with imatinib bound. Key side chains are displayed and labeled. Imatinib (carbon atoms 
in yellow) binds to the DFG-out conformation. The activation loop tyrosine (Y393) points inward and H-bonds to 
the catalytic aspartate in the kinase domain. B) The active site of Lck with imatinib bound. The same side chains are 
labeled as in A. Imatinib binds to the Lck activation loop in a manner analogous to the Abl kinase domain. Unlike 
Abl, however, the activation loop adopts an extended conformation, with the tyrosine autophosphorylation site 
(Y394) exposed. C) WH-4-124-2 (carbon atoms in cyan) was aligned with the analogous portion of imatinib using 
smina, a modified form of AutoDock Vina developed by the Camacho group (Computational and Systems Biology, 
University of Pittsburgh School of Medicine). WH-4-124-2 was readily accommodated by the imatinib-binding 
conformation of the Lck kinase domain, with only minimal changes to the crystallographic positions of side chains 
that come in close contact with the compound. D and E show the structures of imatinib and WH-4-124-2 with the 
overlapping portion highlighted in red. 
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WH-4-124-2 was accommodated by the conformation of the imatinib-bound Lck active site, 
supporting the idea that this inhibitor also prefers the DFG-out state of the kinase active site. A 
similar docking routine was also performed using the X-ray crystal structure of the c-Src kinase 
domain bound to imatinib (PDB: 2OIQ) and yielded an almost identical result, although the 
activation loop is not resolved in this structure (data not shown). In summary, this docking model 
suggests that binding of the pFAK peptide and displacement of the SH3-SH2 regulatory subunits 
allows the kinase to adopt the DFG-out conformation, which in turn is trapped by the inhibitor. 
3.4 DISCUSSION 
In this study, we describe a screening assay that has enabled discovery of a 
conformationally selective inhibitor of the c-Src protein tyrosine kinase. SFKs are involved in a 
wide variety of cellular signaling pathways and most cells express multiple members of Src-
kinase family, making the search for isoform- and pathway-selective inhibitors difficult. Rather 
than focusing on the kinase itself, we developed an assay method that models a disease-specific 
conformation of c-Src that is induced by interaction with FAK. Using a synthetic tyrosine 
phosphopeptide containing the natural FAK sequence known to bind to the SH3 and SH2 
domains of c-Src, we first identified screening assay conditions where Src-YEEI activity was 
dependent on the presence of the pFAK peptide. Comparative studies with shorter peptides that 
bind only to the SH3 (VSL12) or the SH2 (pYEEI) domains individually demonstrated that 
displacement of both intramolecular interactions was required for maximal activation of Src-
YEEI. Using pFAK-activated Src-YEEI, we then screened a small library of kinase-biased 
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inhibitors and identified WH-4-124-2, an aminopyrimidinyl carbamate with enhanced potency 
for Src-YEEI in the presence of the pFAK peptide. This compound exhibited five-fold greater 
potency for the Src-pFAK peptide complex relative to Src-YEEI alone in both endpoint and 
kinetic kinase assays. Interestingly, a smaller structural analog of WH-4-124-2 showed no 
preference, supporting the idea that WH-4-124-2 stabilizes a specific conformation of the kinase 
active site that is induced by interaction with the pFAK peptide. 
Docking studies with WH-4-124-2 and the imatinib-bound crystal structures of both the 
Lck and c-Src kinase domains suggest that binding to the pFAK peptide may induce a unique 
DFG-out conformation that is preferentially inhibited by this compound. In this conformation, 
the αC-helices of both kinase domains are rotated inward, allowing the formation of the 
conserved lysine to glutamate salt bridges. The DFG motif at the distal end of the activation loop 
in each kinase is also rotated outward, in the same manner originally observed for imatinib 
binding to the Abl kinase domain. However, in the Lck structure, the autophosphorylation site is 
also extended outward, although the tyrosine is not phosphorylated (this region is not resolved in 
the c-Src kinase domain structure with imatinib). Using the structural overlap with imatinib as a 
starting point, WH-4-124-2 was readily docked into this unique Lck kinase domain 
conformation, requiring only minimal changes to the positions of side chains already present in 
the crystal structure. The implication, therefore, is that pFAK peptide binding may induce this 
kinase domain conformation in c-Src, thereby accounting for preferential inhibition of the kinase 
by this compound in the presence of the pFAK peptide. Whether or not binding to full-length 
FAK results in similar changes to the c-Src active site in a cellular context will require further 
investigation. Nevertheless, these studies support the more general concept that unique disease-
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state specific conformations of Src-family kinases exist in cells that may be amenable to 
selective inhibition with active-site inhibitors. 
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4.0  GENERAL DISCUSSION 
The Src-family of kinases has been extensively studied as a whole, yet there is still much 
to be learned about the regulation of individual family members. In this study, I have shown 
differences in regulation of four of the Src-family members through extensive biochemical and 
kinetic studies. Further, I have shown that it is possible to target a specific kinase conformation 
induced by high-affinity ligand binding with a small molecule kinase inhibitor. The data 
presented here provides insight into a new way of targeting a specific member of a homologous 
protein family through targeting specific active kinase conformations.  
I hypothesized that regulation of the Src-family members would vary based on the 
phylogenetic breakdown of the eight members into two subfamilies. The experiments presented 
in Chapter 2 examined the regulation of two kinases from each subfamily: c-Src and Fyn from 
subfamily A and Hck and Lyn from subfamily B. Each of these members was chosen based on 
previous work from our laboratory, literature available on the known mechanisms of regulation, 
and evidence that supported a difference in regulation between subfamily members. 
Interestingly, results presented here have shown that differences in regulation cannot be 
explained solely by sequence differences, but are in fact unique for each family member.  
The SFKs are kept in a downregulated state by two intramolecular interactions. 
Disruption of either one or both of these interactions has been shown to result in kinase 
activation for multiple members of the kinase family. Mutation of the C-terminal tail tyrosine in 
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various members of each subfamily results in kinase activation, demonstrating an absolute 
requirement for tail phosphorylation by Csk in kinase regulation. The diversity of control among 
the family members by the SH3:linker interaction is less clear. For most of the SFKs, it is not 
known whether disruption of one interaction requires the disruption of the other before the kinase 
can become activated. The exception to this is Hck, as studies have confirmed that the tail 
remains bound to the SH2 domain while Hck is bound and activated by Nef. For c-Src, however, 
it was possible that when activated by ligand binding to the SH3 domain, a conformational 
change resulted in the release of the tail from the SH2 domain before kinase activation. The 
studies performed here were a means to elucidate this mechanism.  
In Chapter 2 of this thesis, I focused on SH3:linker displacement-induced activation of 
the Src-family kinases. By using SFK proteins with YEEI-tail mutations that increased the 
affinity for the SH2 domain, I was able to ensure that kinase activation would not be influenced 
by this intramolecular interaction and was due only to SH3:linker displacement. In addition, it 
was imperative to ensure that there would be no bias in the system regarding the ligand used to 
displace the SH3:linker interaction. In past studies of SH3 ligand binding, the VSL12 peptide 
was discovered as a high-affinity ligand for the c-Src SH3 domain. In this study, VSL12 was 
confirmed to have similar affinities for the isolated SH3 domains of all of the SFKs tested in 
SPR binding assays. To ensure that the peptide could bind to the downregulated kinases for use 
in kinase assays, I also measured the affinity for the near-full-length proteins. The result was 
surprising, as the affinity increased roughly 1000-fold compared to the isolated SH3 domains. 
The expectation for this experiment was that there would be a lower affinity, or at least a lower 
rate of association, for the near-full length proteins for VSL12, as there would be competition for 
the SH3 domain from SH2-kinase linker which is bound in the downregulated state. However, 
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the association rates of the peptide to the isolated SH3 domain and the near full length kinase 
were nearly identical for each SFK. Surprisingly, the dissociation rates were 1000-fold lower for 
the near-full-length proteins than for the isolated SH3 domains. This suggests that VSL12 
binding to the SH3 domain in the context of the entire protein induces a favorable, stabilized 
conformation, which will require further study to establish. Another explanation for the higher 
affinity is that the VSL12 peptide actually binds to a second site on the near-full length kinase 
domain. The binding affinity of VSL12 has been measured for the isolated SH3, SH2, tandem 
SH3-SH2, and SH3-SH2-linker proteins from c-Src, Fyn, Hck, and Lyn. None of these results 
suggest a second binding site in any of these areas of the protein, and there is no evidence in the 
literature to suggest that the peptide would bind on its own to the isolated kinase domain. 
Furthermore, if there were a second binding site, there would likely be a different rate of 
association since there would be more binding events occurring at those additional sites. There 
are currently plans underway to test this by SPR using the isolated kinase domain proteins and 
eliminate the possibility of a second binding site for the peptide.  
To test whether the binding of VSL12 actually stabilizes the complex, structural 
dynamics studies could be utilized. Using hydrogen exchange mass spectrometry (HXMS, 
(210)), the changes in protein structure could be investigated by comparing Src-YEEI in the 
absence and presence of the peptide. This technique measures the incorporation of deuterium 
into solvent-exposed areas of a protein. Binding of the peptide would potentially prevent 
deuterium exchange in certain areas that are covered by peptide binding. However, other areas 
may become more solvent-exposed through conformational rearrangements and consequently 
incorporate more deuterium, since the peptide is known to activate the kinase. These changes can 
be mapped to specific areas of the protein structure by analysis of changes in mass of peptide 
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sequences. If the hypothesis that VSL12 induces a stabilized conformation of the kinase is true, 
this technique would enable us to determine if and where the peptide makes contact with the 
kinase domain to do so. These data in addition to an x-ray crystal structure of Src-YEEI in 
complex with VSL12 would be the most useful to visualize how the conformation of the entire 
kinase changes in response to SH3:linker displacement.  
Despite the surprising result of the high-affinity binding of VSL12 to the near-full-length 
kinases, I was able to validate the use of VSL12 as an agonist for the SFKs with equal affinity 
for each family member. Subsequently, I showed that this peptide was able to activate all SFKs 
tested to varying degrees. This disproves the original hypothesis, which stated that SrcA 
subfamily members would not be susceptible to activation by SH3:linker displacement alone. 
However, the activation mechanisms of all family members are not the same, which supports the 
idea that regulation across the kinase family is diverse, despite the homology of the family 
members. It was not surprising that the activity of Src-YEEI and Fyn-YEEI was similar in 
response to VSL12 binding since they are members of the same subfamily. The difference 
between Hck and Lyn was unexpected because they are the closest phylogenetic relatives in the 
SrcB subfamily. Similarly, recent evidence supports opposing roles for c-Src and c-Yes in both 
development and cancer. These two family members are the closest phylogenetic relatives in the 
SrcA subfamily, yet their functions are proving to be unique. This is not simply a consequence of 
expression patterns as these are two of the three SFKs (Fyn being the third) that are expressed 
ubiquitously. At the time this study was designed, the evidence for differences between c-Src and 
c-Yes was not as prevalent. Continuation of this study with Yes-YEEI would be a logical next 
step to further the evidence for diversity in the regulation of the Src kinase family.  
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 Another significant finding in this study was that autophosphorylation of Src-
YEEI seemed to prime the kinase for activity, while it had no such effect on Hck-YEEI. The 
overall activity of both autophosphorylated kinases was increased in both the absence and 
presence of the peptide, showing that autophosphorylation of the activation loop alone does not 
stimulate the kinase to its maximum activity. However, the result with Hck-YEEI showed that 
activity induced by SH3 domain displacement is not influenced by the phosphorylation state of 
the kinase while the result with Src-YEEI supports a different mechanism of regulation. Further 
studies are in progress with linker mutants of both Src-YEEI and Hck-YEEI that will abolish the 
SH3:linker interaction. These experiments will hopefully determine whether the differences 
observed between Src-YEEI and Hck-YEEI are merely result of peptide disassociation and linker 
reassociation rather than a real difference in regulation between the two kinases.  
 Overall, the study in Chapter 2 has utilized knowledge gained from previous 
research on the regulation of the SFKs and provides a new view of the diversity in kinase 
regulation. Some differences may be accounted for by variation in the cellular expression 
patterns of the kinases. For example, the results presented here suggest that Hck is generally 
more susceptible to activation by perturbation of any interaction that supports downregulation of 
activity, and this may correspond to a requirement for fast Hck activation in a cellular context. 
Conversely, c-Src may be more tightly regulated and require more than just displacement of one 
interaction to result in maximal kinase activity. Alternatively, different levels of c-Src activity 
may be elicited by activation through different mechanisms. For example, in the context of c-Src 
activation by FAK, both intramolecular interactions are displaced by FAK binding, resulting in 
complete release of autoinhibitory control. In a situation where c-Src is activated by 
displacement of only one interaction, it may be in a context where less c-Src activity is required. 
 106 
This could be an evolutionary mechanism for controlling the amount of activity elicited from one 
kinase. Results from Chapter 3 support that different levels of kinase activity result from 
displacement of one, the other, or both intramolecular interactions.  
 In Chapter 3, I focused on exploiting the differences in mechanisms of kinase 
activation to screen for conformationally selective inhibitors of c-Src kinase activity. As 
mentioned above, FAK activates c-Src by binding both the SH3 and SH2 domains, resulting in a 
loss of regulatory control of activity by these domains. Rather than trying to model the system 
using the full-length FAK protein, I was able to use a peptide comprised of the FAK sequence 
that binds the c-Src SH3 and SH2 domains, pFAK. This peptide activated the Src-YEEI protein 
in kinase assays better than peptides that targeted either the SH3 or SH2 domain alone. Even 
when using both of the individual domain-binding peptides together, the activation by the pFAK 
peptide, which has the binding sequences for both domains in tandem, was much higher. This 
supports the idea presented in Chapter 2 that disruption of the regulatory control by the different 
intramolecular interactions can have a different result.  
 By determining conditions in the Z’Lyte in vitro kinase assay such that activation 
of Src-YEEI was dependent on the presence of the pFAK peptide, I was able to ensure that any 
active protein in the assay would be in a pFAK-induced conformation. Using these assay 
conditions, I screened a kinase-biased inhibitor library to see if inhibitors could be identified that 
preferentially inhibited the pFAK-bound state of Src. Out of 586 screened compounds, 97 were 
able to inhibit the Src-YEEI:pFAK complex in the primary screen. As a counterscreen, I used a 
concentration of Src-YEEI protein alone that resulted in the same basal level of activity that was 
elicited by the Src-YEEI:pFAK complex. The mechanism of activation in the Src-only kinase 
reactions is likely trans-autophosphorylation of the activation loop, as there are no ligands 
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present to displace the intramolecular regulatory interactions. Only 21 of the 97 compounds 
tested here were selective for the Src-YEEI:pFAK complex. Further testing of these compounds 
identified WH-4-124-2 as the most potent and selective inhibitor of the Src-YEEI:pFAK 
complex. This compound showed a five-fold selectivity for the complex in endpoint and kinetic 
kinase assays. 
 Although the compound is selective for the pFAK-induced conformation of Src-
YEEI compared to Src-YEEI alone, there is still a matter of selectivity of Src-YEEI over other 
members of the kinase family. Currently, plans are underway to test the ability of the pFAK 
peptide to activate Hck-YEEI, Fyn-YEEI, and Lyn-YEEI. This will not only extend the study 
performed in Chapter 2, but will also enable me to determine whether the conformation of c-Src 
induced by FAK binding is unique to Src. I would predict that Fyn-YEEI will show similar 
inhibition by WH-4-124-2 due to the similarities observed in Chapter 2, as well as evidence that 
Fyn is bound and activated by FAK in cells as well. There is also uncertainty as to whether this 
active conformation is induced solely by FAK or if another ligand can bind and induce a similar 
conformation. Studies are also underway to test this question using VSL12 and pYEEI, the 
peptides used in Chapter 2 that bind to the individual SH3 or SH2 domains, respectively.  
 In addition to the discovery of the selective compound WH-4-124-2, a structural 
analog, WH-4-023, was also discovered and shows a similar level of potency but no selectivity 
for either the pFAK bound or unbound kinase. Based on the modeling studies performed with 
WH-4-124-2 and the Lck kinase domain bound to imatinib, we can speculate that the selectivity 
observed with WH-4-124-2 is due to the imatinib-like part of the structure, which is not present 
in WH-4-023. The facile docking of WH-4-124-2 to the imatinib-bound conformation of Lck 
suggests that the pFAK-bound conformation of Src-YEEI may also be sensitive to inhibition by 
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imatinib itself. Therefore, plans are underway to test the ability of imatinib to inhibit the Src-
YEEI:pFAK complex. Experiments have already demonstrated that imatinib has no effect on 
Src-YEEI alone. In addition, further studies will be required to elucidate the mechanism of 
selectivity of WH-4-124-2. Crystallographic studies would be ideal in the determination of the 
actual binding mode of the compound to Src-YEEI in the pFAK-bound state.  
 This dissertation provides strong evidence for the diversity in regulation among 
the Src-kinase family. Despite their homology and apparent redundancy in certain cellular 
processes, eight SFKs are conserved and functional in mammalian species. This suggests that in 
cells, each family member has a unique role and function. Otherwise, evolutionary mechanisms 
would likely result in the loss of expression of the individual kinase gene. Therefore, it is 
important to understand the differences in the mechanisms of kinase regulation. While the search 
for selective inhibitors of SFKs has remained elusive, a new approach could be to target a 
disease-induced conformation of that kinase, as I have demonstrated here. This would not only 
target the specific member involved in deregulation of cellular processes, but would target the 
specific effects that result from the deregulation, rather than all effects of that kinase in a cell. 
The results presented here will hopefully lay the foundation for further exploitation of these 
differences as a means to generate selective inhibitors. 
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APPENDIX A 
INHIBITION RESULTS FROM SCREENED COMPOUNDS 
Table 7. Inhibition of Src-YEEI +/- pFAK by entire kinase-biased library 
Compound % Inhibition of Src + pFAK % Inhibition of Src Alone Selectivity Ratio 
1 -1.05676 1.655786 -0.63822 
2 0.163812 0.3165 0.517573 
3 6.932333 0.723222 9.58534 
4 8.072438 5.989337 1.347802 
5 9.060375 -0.00341 -2655.99 
6 9.992882 1.834704 5.446591 
7 10.35875 2.077826 4.98538 
8 10.3591 2.962374 3.496891 
9 10.95063 0.190116 57.59982 
10 10.96882 1.396072 7.856915 
11 11.07077 0.416142 26.60337 
12 11.23091 6.413868 1.751035 
13 11.23474 0.178414 62.9699 
14 11.34642 0.072944 155.5488 
15 11.78764 4.872591 2.419173 
16 11.93701 0.472202 25.27947 
17 11.96135 2.030002 5.892281 
18 11.97477 0.080071 149.552 
19 12.04613 0.526966 22.85939 
20 12.06802 2.265138 5.327719 
21 12.09864 2.009403 6.021013 
22 12.1222 0.45286 26.76807 
23 12.15354 0.668505 18.18018 
24 12.16973 1.37497 8.850902 
25 12.25697 0.492325 24.89607 
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26 12.36962 0.334352 36.99582 
27 12.39133 1.243784 9.96261 
28 12.47908 1.179349 10.58133 
29 12.49611 1.205771 10.36358 
30 12.5152 0.233681 53.55671 
31 12.54649 0.610832 20.54 
32 12.59205 0.312733 40.26446 
33 12.59697 2.413911 5.21849 
34 12.63199 3.235642 3.904013 
35 12.71639 0.169952 74.82322 
36 12.92122 2.385509 5.416547 
37 13.03294 0.433512 30.06363 
38 13.03578 0.811205 16.06965 
39 13.06999 0.189005 69.15156 
40 13.13507 0.976308 13.45382 
41 13.29562 0.306635 43.35971 
42 13.36031 1.875123 7.125031 
43 13.39715 0.880146 15.22151 
44 13.43963 0.50675 26.5212 
45 13.50299 0.575847 23.44891 
46 13.69583 1.125914 12.16419 
47 13.79031 0.562839 24.50136 
48 13.79358 3.596688 3.835078 
49 13.79764 2.301167 5.99593 
50 13.809 1.165683 11.84628 
51 13.91971 0.330409 42.12871 
52 13.97795 1.161069 12.03887 
53 13.9996 1.70548 8.208599 
54 14.04175 3.491324 4.021897 
55 14.0982 3.776451 3.733188 
56 14.20927 0.766384 18.54066 
57 14.29919 1.963669 7.281872 
58 14.33865 0.339257 42.26485 
59 14.44022 1.991091 7.252417 
60 14.64863 5.43356 2.695954 
61 14.74163 1.850993 7.964175 
62 14.78307 0.476555 31.0207 
63 14.81299 0.852896 17.36787 
64 14.90194 4.322087 3.447858 
65 14.91428 5.139667 2.901798 
66 15.04176 0.171605 87.65331 
67 15.14022 1.316583 11.49963 
68 15.15493 0.5189 29.20587 
 111 
69 15.207 1.602411 9.490073 
70 15.21608 5.626585 2.704319 
71 15.26731 1.384225 11.0295 
72 15.28375 2.238258 6.828411 
73 15.36021 1.668255 9.207347 
74 15.39262 3.541223 4.346697 
75 15.43114 4.433202 3.480811 
76 15.4541 0.711395 21.72366 
77 15.45672 2.489578 6.20857 
78 15.46411 3.688976 4.19198 
79 15.47341 5.432503 2.848303 
80 15.52328 1.777295 8.734217 
81 15.57905 1.727185 9.019908 
82 15.595 5.460282 2.85608 
83 15.59569 5.031421 3.099659 
84 15.59698 0.990891 15.74036 
85 15.61003 4.829234 3.232404 
86 15.66209 2.21828 7.060464 
87 15.71785 2.368916 6.635042 
88 15.72532 1.814356 8.667164 
89 15.731 1.032196 15.24032 
90 15.73691 0.649149 24.24239 
91 15.77856 1.276891 12.35701 
92 15.79068 1.04673 15.08572 
93 15.80384 0.968309 16.32108 
94 15.81084 2.128113 7.429512 
95 15.81354 2.255275 7.011803 
96 15.81975 1.853161 8.536629 
97 15.86506 3.168779 5.006678 
98 15.89999 0.306859 51.81527 
99 15.9053 4.044773 3.93231 
100 16.00257 -0.0182 -879.146 
101 16.0104 4.177361 3.832658 
102 16.01528 1.705898 9.388187 
103 16.03526 2.109545 7.601289 
104 16.03562 0.704495 22.76187 
105 16.08144 5.147984 3.123833 
106 16.11301 0.491412 32.78921 
107 16.11854 1.899874 8.484007 
108 16.14144 0.415573 38.8414 
109 16.16575 5.708494 2.831877 
110 16.18453 0.422172 38.33637 
111 16.30427 1.682273 9.691811 
 112 
112 16.33012 2.636524 6.193808 
113 16.35565 1.524521 10.72838 
114 16.40199 4.953346 3.311295 
115 16.40327 9.409703 1.74323 
116 16.43318 2.531134 6.49242 
117 16.44527 0.991622 16.58421 
118 16.48619 2.344932 7.030565 
119 16.50209 1.011425 16.31569 
120 16.51153 1.771861 9.318749 
121 16.54542 1.841976 8.982428 
122 16.56777 0.889823 18.61917 
123 16.57569 2.783934 5.954053 
124 16.58759 -0.76161 -21.7796 
125 16.65627 3.040621 5.477919 
126 16.71397 2.315421 7.218546 
127 16.75849 1.0254 16.34337 
128 16.75948 2.132881 7.857674 
129 16.81444 2.1346 7.877091 
130 16.92674 1.333665 12.69189 
131 16.9689 1.684544 10.07329 
132 16.9858 7.49533 2.266185 
133 17.04722 0.985629 17.29577 
134 17.11595 1.677682 10.20214 
135 17.12142 3.604939 4.749435 
136 17.12829 2.862867 5.982914 
137 17.1423 2.063506 8.307364 
138 17.14735 4.900618 3.499017 
139 17.15576 1.016171 16.88274 
140 17.16765 4.231094 4.057495 
141 17.17136 4.254814 4.035748 
142 17.17161 1.257587 13.65441 
143 17.18536 1.696379 10.13061 
144 17.2227 5.219989 3.299374 
145 17.29945 4.691753 3.687205 
146 17.31235 6.810871 2.541871 
147 17.3157 3.056804 5.664641 
148 17.32184 1.058492 16.36464 
149 17.3592 1.802853 9.628739 
150 17.46806 1.222445 14.28945 
151 17.46919 4.584605 3.810403 
152 17.55299 3.803062 4.615489 
153 17.58265 2.280118 7.71129 
154 17.6048 0.6494 27.10934 
 113 
155 17.60619 1.735818 10.14288 
156 17.63935 2.263221 7.793915 
157 17.68061 3.076253 5.747449 
158 17.68725 2.77381 6.376515 
159 17.73131 2.894009 6.126901 
160 17.77415 0.531531 33.43953 
161 17.80178 3.004909 5.924233 
162 17.82029 1.357896 13.12345 
163 17.83988 3.918228 4.553047 
164 17.84686 5.58684 3.194445 
165 17.85086 1.860486 9.59473 
166 17.86324 2.84523 6.278312 
167 17.8862 2.481988 7.206399 
168 17.94522 0.759405 23.63063 
169 17.94541 5.513314 3.254922 
170 17.96896 1.620392 11.08926 
171 18.012 6.160427 2.923823 
172 18.01849 6.850245 2.630342 
173 18.04526 6.280004 2.873448 
174 18.10991 1.848794 9.795526 
175 18.13973 2.653361 6.836509 
176 18.17835 4.81625 3.774379 
177 18.18355 1.994071 9.118808 
178 18.18915 2.883705 6.307562 
179 18.26126 3.395294 5.378402 
180 18.26662 5.847018 3.124091 
181 18.29516 4.875219 3.752685 
182 18.39449 0.719205 25.57614 
183 18.42219 6.063894 3.038012 
184 18.42479 4.512916 4.08268 
185 18.54931 3.399552 5.456398 
186 18.56268 1.050138 17.67642 
187 18.61456 11.33862 1.641695 
188 18.64668 11.3112 1.648515 
189 18.67018 0.925332 20.17673 
190 18.71215 8.306225 2.252787 
191 18.71628 4.137643 4.523416 
192 18.77632 2.098926 8.945681 
193 18.79972 5.827661 3.225945 
194 18.86006 0.218172 86.44573 
195 18.86682 4.612238 4.0906 
196 18.8917 1.145236 16.4959 
197 18.91364 4.607624 4.104857 
 114 
198 18.91686 6.585651 2.872436 
199 18.94533 6.883961 2.752097 
200 18.94985 7.225188 2.622748 
201 19.00018 9.366412 2.028544 
202 19.02491 1.535469 12.39029 
203 19.03255 8.446746 2.253241 
204 19.04837 2.697357 7.061863 
205 19.06512 4.740793 4.021504 
206 19.0805 1.000644 19.06821 
207 19.08629 3.196386 5.97121 
208 19.09558 2.883811 6.621648 
209 19.09763 1.477835 12.9227 
210 19.1226 2.209382 8.65518 
211 19.17345 10.73205 1.786561 
212 19.18682 2.194995 8.741165 
213 19.20305 2.921629 6.57272 
214 19.23632 2.354028 8.171661 
215 19.26003 1.830156 10.52371 
216 19.28432 0.256555 75.16644 
217 19.30576 3.366114 5.735325 
218 19.30644 1.904126 10.13926 
219 19.32286 5.8618 3.296403 
220 19.33435 10.33571 1.870636 
221 19.34707 3.123534 6.193967 
222 19.35713 0.68338 28.32557 
223 19.41792 1.509819 12.86109 
224 19.4511 2.434682 7.989175 
225 19.4664 0.689136 28.24756 
226 19.58305 1.108829 17.66101 
227 19.59132 2.269926 8.630822 
228 19.59706 0.804041 24.37319 
229 19.60199 1.416402 13.83928 
230 19.65425 2.787192 7.051632 
231 19.68339 3.144848 6.258934 
232 19.69547 1.423277 13.83811 
233 19.70379 0.738251 26.68984 
234 19.74426 0.134214 147.1102 
235 19.76831 2.260167 8.746395 
236 19.79042 6.03248 3.280644 
237 19.84852 2.413714 8.22323 
238 19.85368 3.411658 5.819363 
239 19.87076 4.593318 4.326015 
240 19.88866 0.434671 45.75565 
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241 19.92979 5.557315 3.586227 
242 19.95027 1.342512 14.8604 
243 19.95534 1.675157 11.91252 
244 19.9575 0.853028 23.39607 
245 20.08805 3.86926 5.191704 
246 20.15019 2.798649 7.199969 
247 20.15795 6.828059 2.952222 
248 20.16847 1.933273 10.43229 
249 20.18099 7.242125 2.786611 
250 20.19599 4.046453 4.991037 
251 20.24027 5.74521 3.522982 
252 20.24227 1.61215 12.55607 
253 20.25652 1.829986 11.06922 
254 20.26385 2.500671 8.103367 
255 20.27183 1.659013 12.21921 
256 20.28649 10.62399 1.909499 
257 20.31189 3.15401 6.440018 
258 20.36185 0.564643 36.06145 
259 20.42407 3.049191 6.698195 
260 20.43454 4.835686 4.225779 
261 20.49723 2.961052 6.922279 
262 20.50293 1.948552 10.52214 
263 20.54781 7.142816 2.87671 
264 20.594 1.771467 11.62539 
265 20.68611 0.911173 22.70271 
266 20.70482 1.164637 17.77791 
267 20.77176 6.560689 3.166094 
268 20.86818 1.992543 10.47314 
269 20.87983 0.858199 24.32981 
270 20.93926 4.424301 4.732784 
271 20.98057 2.596462 8.080445 
272 21.01502 1.977238 10.62847 
273 21.06786 3.256582 6.469315 
274 21.06871 1.680771 12.53514 
275 21.11059 4.090139 5.161338 
276 21.18226 2.613532 8.104839 
277 21.22806 6.644819 3.194679 
278 21.23069 2.13653 9.936997 
279 21.23992 1.467505 14.47348 
280 21.27217 2.957533 7.192536 
281 21.30167 5.366592 3.969311 
282 21.35399 2.814206 7.587929 
283 21.43445 4.040181 5.30532 
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284 21.45311 2.697569 7.952758 
285 21.4544 0.76346 28.10153 
286 21.45599 9.693888 2.213352 
287 21.46337 1.407575 15.24847 
288 21.50144 1.626783 13.21716 
289 21.52096 5.698776 3.776418 
290 21.61413 4.682928 4.615515 
291 21.6365 9.862598 2.193793 
292 21.65885 2.342564 9.24579 
293 21.66703 5.086634 4.259601 
294 21.67073 2.786231 7.777795 
295 21.71572 0.904725 24.00256 
296 21.77027 3.215607 6.77019 
297 21.8215 6.767834 3.224297 
298 21.82485 2.363574 9.233834 
299 21.85556 6.471891 3.376997 
300 21.88715 1.085466 20.16383 
301 21.89106 0.802309 27.28506 
302 21.89941 2.140717 10.22994 
303 21.90803 1.829838 11.97266 
304 21.91875 2.862399 7.657474 
305 21.94416 12.06805 1.818368 
306 21.98736 9.362538 2.34844 
307 22.03226 0.808497 27.25088 
308 22.07407 4.366075 5.055816 
309 22.07567 2.480137 8.900986 
310 22.12202 6.189841 3.573923 
311 22.15849 6.713122 3.300773 
312 22.17154 2.204149 10.059 
313 22.21643 1.176531 18.883 
314 22.24552 5.987367 3.715409 
315 22.25149 5.849676 3.803885 
316 22.34234 4.510814 4.953061 
317 22.36725 2.448038 9.136807 
318 22.40685 5.03983 4.445954 
319 22.40814 0.741583 30.21664 
320 22.45977 8.557571 2.624549 
321 22.46989 2.725341 8.244799 
322 22.49281 2.989513 7.523903 
323 22.51359 0.564222 39.90204 
324 22.52635 2.673513 8.425749 
325 22.52802 4.497976 5.008479 
326 22.52815 2.856011 7.887976 
 117 
327 22.64176 72.71791 0.311364 
328 22.65512 1.914439 11.83382 
329 22.83849 3.528867 6.471905 
330 22.85895 2.949407 7.750354 
331 22.88449 2.362755 9.685509 
332 22.93358 6.554792 3.49875 
333 22.95248 0.765936 29.96657 
334 23.00546 3.119458 7.374826 
335 23.0519 4.010902 5.747311 
336 23.06352 0.963265 23.94307 
337 23.09069 1.518701 15.20423 
338 23.1162 3.114203 7.42283 
339 23.12427 4.719586 4.899639 
340 23.15909 3.9591 5.849585 
341 23.20349 3.034142 7.647463 
342 23.23682 0.720193 32.2647 
343 23.26771 2.633605 8.83493 
344 23.31819 8.641714 2.69833 
345 23.32219 5.504323 4.237068 
346 23.3589 2.093275 11.15902 
347 23.37214 2.771005 8.434535 
348 23.41181 2.273653 10.297 
349 23.44929 2.072386 11.31512 
350 23.56061 11.45885 2.056107 
351 23.67623 3.585305 6.603685 
352 23.70001 0.891746 26.57708 
353 23.85296 0.120265 198.3369 
354 23.92814 5.604663 4.269328 
355 23.94154 6.788116 3.526979 
356 23.97567 3.599649 6.660557 
357 24.01254 2.673408 8.981997 
358 24.09887 2.181363 11.04762 
359 24.27753 2.703082 8.981426 
360 24.3443 2.114586 11.51256 
361 24.50473 4.554958 5.379792 
362 24.52534 5.486157 4.470404 
363 24.60242 1.432879 17.16992 
364 24.61553 1.615061 15.24124 
365 24.81927 1.738463 14.27656 
366 24.84319 3.038074 8.17728 
367 24.84698 2.704623 9.186856 
368 24.87162 2.433226 10.22166 
369 24.90368 8.862551 2.80999 
 118 
370 24.99238 4.563348 5.476764 
371 24.99341 3.951553 6.324958 
372 24.99756 4.706412 5.311384 
373 25.02731 3.269253 7.655361 
374 25.1131 5.228041 4.803538 
375 25.131 0.661042 38.01726 
376 25.21191 3.152715 7.996888 
377 25.23346 3.318526 7.603815 
378 25.27587 5.541839 4.560917 
379 25.37291 2.635982 9.625601 
380 25.54346 4.252182 6.007141 
381 25.62895 2.365323 10.83528 
382 25.63698 2.210234 11.59921 
383 25.76067 4.951151 5.202966 
384 25.84048 5.62677 4.592417 
385 25.90044 0.541828 47.80199 
386 25.95216 0.123742 209.7272 
387 26.00165 27.96519 0.929786 
388 26.10944 3.363417 7.762773 
389 26.1432 5.969808 4.379235 
390 26.17746 5.881064 4.451144 
391 26.21946 1.563799 16.76652 
392 26.30028 2.072044 12.69292 
393 26.35175 7.022937 3.75224 
394 26.37367 2.706137 9.745875 
395 26.64323 3.900551 6.830633 
396 26.70871 2.248114 11.8805 
397 26.75591 1.471119 18.18746 
398 26.92577 0.688596 39.10243 
399 26.92975 2.56796 10.48682 
400 26.97072 1.540368 17.50927 
401 27.02576 2.028461 13.32328 
402 27.06865 3.311966 8.172984 
403 27.13756 4.425018 6.132756 
404 27.22 1.033836 26.32914 
405 27.39722 4.392506 6.237265 
406 27.51366 5.983969 4.597894 
407 27.71676 7.866016 3.523608 
408 27.76915 2.25391 12.32043 
409 27.86996 5.846687 4.766794 
410 28.06458 5.413553 5.184133 
411 28.10224 6.240326 4.503329 
412 28.11628 2.617852 10.74021 
 119 
413 28.17053 5.919262 4.759129 
414 28.18318 7.381958 3.817845 
415 28.25317 3.627821 7.787917 
416 28.41126 7.365603 3.857289 
417 28.44473 4.138555 6.873107 
418 28.49778 4.152056 6.863535 
419 28.77416 5.897155 4.879329 
420 28.84867 1.73684 16.60986 
421 28.99892 3.739222 7.755334 
422 29.24637 5.068919 5.769745 
423 29.48036 6.367003 4.630179 
424 29.69964 12.15198 2.444015 
425 29.72595 0.192798 154.182 
426 29.75817 2.668217 11.15283 
427 29.76183 3.511646 8.475179 
428 29.81552 0.740569 40.2603 
429 29.87519 2.091589 14.28349 
430 30.07509 3.277198 9.177075 
431 30.34321 6.535819 4.642603 
432 30.64462 6.739447 4.547052 
433 30.75738 8.233717 3.73554 
434 31.29992 6.94687 4.505615 
435 31.48084 3.963236 7.943216 
436 31.52943 0.82734 38.10941 
437 31.6026 2.634184 11.99711 
438 31.70059 4.996491 6.344571 
439 31.78471 3.673678 8.652012 
440 31.98826 1.840115 17.38384 
441 32.87826 8.054362 4.082044 
442 32.89764 5.275902 6.235452 
443 32.98506 12.49736 2.639362 
444 32.99549 2.64094 12.49384 
445 33.6758 1.619684 20.79159 
446 34.11444 8.424692 4.04934 
447 34.36854 4.843944 7.095156 
448 34.81288 2.28041 15.26607 
449 34.87136 6.293887 5.540513 
450 34.96772 8.937881 3.912306 
451 35.28426 1.32676 26.59431 
452 35.28474 2.106262 16.7523 
453 35.55667 3.408221 10.43262 
454 35.57448 6.035911 5.893804 
455 35.60313 1.23368 28.8593 
 120 
456 35.7842 20.7126 1.727654 
457 35.85878 5.545079 6.466775 
458 36.01615 2.109476 17.07351 
459 36.03274 9.348708 3.854301 
460 36.09289 3.786467 9.532075 
461 36.54945 2.662703 13.72645 
462 37.65126 2.628152 14.32614 
463 38.08169 2.219599 17.15702 
464 38.96175 10.8227 3.600004 
465 39.51385 2.251894 17.54694 
466 39.54234 3.249312 12.16945 
467 39.72978 2.159644 18.39645 
468 39.76753 12.55135 3.168386 
469 40.94203 2.241568 18.2649 
470 41.03104 2.664609 15.39852 
471 41.03848 2.179901 18.82584 
472 41.32028 7.951909 5.196273 
473 42.93393 3.516578 12.20901 
474 43.12494 43.44659 0.992597 
475 43.18875 10.29582 4.194784 
476 44.11608 2.378152 18.55057 
477 44.51732 3.699749 12.03253 
478 44.97484 17.62204 2.552193 
479 45.38656 4.564718 9.942906 
480 46.12428 35.93889 1.283408 
481 46.14673 5.013126 9.20518 
482 46.93707 16.62757 2.822846 
483 47.65766 2.733428 17.43513 
484 47.7562 9.863722 4.8416 
485 47.83338 3.334384 14.34549 
486 47.97869 4.789824 10.01679 
487 48.32626 16.07747 3.005837 
488 48.54235 14.5496 3.336335 
489 49.22858 9.960055 4.942601 
490 49.64085 5.065599 9.799601 
491 49.7736 5.513021 9.028371 
492 49.91057 13.32076 3.746826 
493 50.21187 12.97195 3.870805 
494 50.56013 59.26862 0.853067 
495 50.82563 22.81096 2.228123 
496 50.97693 24.58849 2.073203 
497 51.10337 39.32116 1.29964 
498 51.46565 48.39147 1.063527 
 121 
499 52.23165 52.6742 0.991598 
500 52.63766 22.37459 2.352564 
501 52.93405 49.51545 1.069041 
502 53.43816 17.31123 3.086908 
503 54.17965 8.980643 6.032937 
504 54.85789 24.09676 2.276567 
505 54.94217 6.032605 9.107536 
506 55.39324 9.008973 6.148674 
507 55.73821 4.461786 12.49235 
508 55.85976 7.533579 7.414771 
509 56.09981 24.3892 2.300191 
510 56.32542 40.57499 1.388181 
511 56.62043 21.80912 2.596182 
512 56.7919 2.936605 19.33931 
513 58.54569 41.7275 1.403048 
514 58.74441 60.98616 0.963242 
515 58.76811 25.94905 2.26475 
516 58.78421 8.941683 6.574178 
517 59.19019 61.95816 0.955325 
518 59.20395 28.68338 2.064051 
519 60.1261 33.78708 1.779559 
520 61.76831 8.230116 7.505156 
521 62.0322 35.39425 1.752607 
522 62.34861 57.76247 1.079397 
523 62.51814 65.08594 0.960548 
524 62.6514 37.93071 1.651733 
525 63.28499 7.825515 8.087007 
526 63.6624 7.452366 8.542576 
527 63.72227 15.0294 4.239842 
528 64.80812 14.20631 4.561925 
529 65.60772 21.87967 2.998569 
530 65.79678 20.69193 3.179827 
531 66.22396 71.1194 0.931166 
532 66.63691 28.34065 2.351283 
533 66.66137 23.25005 2.86715 
534 66.89158 65.58633 1.019901 
535 67.20214 54.48069 1.233504 
536 67.84205 54.65182 1.24135 
537 68.25685 12.99121 5.254077 
538 68.46062 40.79924 1.677988 
539 68.49612 52.18501 1.312563 
540 69.00923 65.82745 1.048335 
541 70.07565 27.04345 2.591224 
 122 
542 70.61014 41.81457 1.688649 
543 70.64229 8.029943 8.797359 
544 71.02607 32.90741 2.158361 
545 71.43963 47.04741 1.51846 
546 73.10076 55.4468 1.318395 
547 73.54171 15.35718 4.78875 
548 74.28116 75.00011 0.990414 
549 74.66246 45.87899 1.627378 
550 75.0141 26.24327 2.858413 
551 75.10517 72.27594 1.039145 
552 75.25645 34.06319 2.209319 
553 75.65577 48.84848 1.548784 
554 75.70339 71.61728 1.057055 
555 76.17291 33.72893 2.258385 
556 76.2484 27.30264 2.792711 
557 76.33412 48.57994 1.571309 
558 76.53089 55.10378 1.38885 
559 76.68709 59.6991 1.28456 
560 77.05621 33.66234 2.289093 
561 77.67972 68.26015 1.137995 
562 77.72795 46.12522 1.685151 
563 78.50181 85.32508 0.920032 
564 78.88049 67.80825 1.163287 
565 78.90148 53.30199 1.480273 
566 79.18738 67.9731 1.164981 
567 79.3689 76.11435 1.042759 
568 79.60867 40.05725 1.987372 
569 80.58981 79.72105 1.010898 
570 80.71724 80.58911 1.00159 
571 80.76031 66.34898 1.217205 
572 81.20856 73.57013 1.103825 
573 81.20908 82.31402 0.986577 
574 81.85259 80.71004 1.014156 
575 81.92597 78.80328 1.039626 
576 82.02912 80.68384 1.016673 
577 82.33925 79.63629 1.033941 
578 82.43232 81.12737 1.016085 
579 82.86357 56.63505 1.463115 
580 82.91347 62.63022 1.323857 
581 86.05231 29.1152 2.95558 
582 86.92015 18.35838 4.734631 
583 89.02011 84.46587 1.053918 
584 90.836 62.53645 1.452529 
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585 91.09277 44.49977 2.047039 
586 102.776 90.46986 1.136024 
 
Percent inhibition of Src-YEEI activity in the presence and absence of the pFAK peptide is shown. Percent 
inhibition is calculated based on the maximum inhibition, where no ATP is present, and the minimum inhibition, 
where only DMSO is present. Compounds are sorted by their percent inhibition of the Src-YEEI:pFAK complex, 
which is reflected in the compound number column. This corresponds to Figure 23A in the main text. The 
compounds characterized in the study are highlighted in gray. Compound 543 is the selective WH-4-124-2 and 
compound 551 is the non-selective analog WH-4-023. 
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APPENDIX B 
COMMONLY USED ABBREVIATIONS 
 
 
 
 
 
 
AIDS Acquired Immunodeficiency Syndrome 
CML Chronic myelogenous leukemia 
Csk C-terminal Src kinase 
ECM Extracellular matrix 
EGFR Epidermal growth factor receptor 
FAK Focal adhesion kinase 
FAT Focal adhesion targeting 
FERM Four-point-one/ezrin/radixin/moesin 
FGFR Fibroblast growth factor receptor 
HIV Human immunodeficiency virus 
PDB Protein data bank 
PDGFR Platelet derived growth factor receptor 
PPII Polyproline type II 
PTP Protein tyrosine phosphatase 
RTK Receptor tyrosine kinase 
SFK Src family kinase 
SH2 Src homology 2 
SH3 Src homology 3 
SPR Surface plasmon resonance 
SYF Src-Yes-Fyn  
TCR T-cell receptor 
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